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Diseases of the upper respiratory tract encompass a plethora of complex multifaceted etiologies 
ranging from acute viral and bacterial infections to chronic diseases of the lung and nasal cavity. 
Due to this inherent complexity, typical treatments often fail in the face of recalcitrant infections 
and/or severe forms of chronic disease, including asthma. Thus, in order to provide improved 
standard of care, the mechanisms at play in hard-to-treat etiologies must be better understood. 
More recently, research has demonstrated a significant association between microbiota and 
many URT diseases. Previous work has also identified species capable of directly inhibiting 
standard treatments used to control asthma exacerbations. Despite an exhaustive collection of 
data characterizing microbiota composition in states of both health and disease, our knowledge 
of what microbiota profiles are observed in what specific disease etiologies is severely lacking. 
Yet, gaining these insights is crucial for the translation of such data into application.  In this 
thesis I sought to: 1) identify gut microbiota profiles associated with severe and treatment 
resistant forms of childhood asthma, and 2) formulate a predictive model to facilitate the 
restructuring of microbiota for desired therapeutic outcomes.  
 
To identify gut microbiota and metabolites enriched in severe and treatment resistant childhood 
asthma, I looked to an ongoing longitudinal human study on vitamin D and childhood asthma. In 
this study, I find several fecal bacterial taxa and metabolites associated with more severe (i.e., 
higher wheeze proportion) and treatment resistant asthma in children at age 3 years. 
Specifically, several Veillonella species were enriched in children with higher wheeze proportion 
and in children that responded poorly to inhaled corticosteroid treatment (ICS) (i.e., non-
responders). Haemophilus parainfluenzae, a species previously identified as enriched in the 
airway of adults with ICS-resistant asthma, was also uniquely enriched in children considered 
ICS non-responders in this study. Several metabolic pathways were also distinctly enriched: 
histidine metabolism was enriched in children with higher wheeze proportion while sphingolipid 
metabolism was enriched in ICS non-responders. Both metabolic pathways have been 
previously identified in association with asthma, further corroborating their role in this disease. 
Yet, this study is the first to identify these taxa and metabolites in children with preexisting and 
treatment resistant asthma. 
 
In the pursuit of improved treatment outcomes for recalcitrant URT diseases, recent efforts have 
turned towards microbiota-based therapies. While such treatments have proven successful in 
the treatment of gastrointestinal infections, these methods have not yet been extended to other 
conditions. Considering this, I ask whether a predictive model describing microbial interactions 
can facilitate the restructuring of microbiota for desired therapeutic outcomes. For this, I use a 
community of nasal microbiota to determine when a simply Lotka-Volterra-like (LV) model is a 
suitable representation for microbial interactions. I then utilize our LV-like model to examine 
whether environmental fluctuations have a major influence on community assembly and 
composition. For this, I looked specifically at pH fluctuations. In this study, I found that LV-like 
models are most suitable for describing community dynamics in complex low nutrient conditions. 
I also identified simple in vitro experiments that can reliably predict the suitability of a LV-like 
model for describing outcomes of a two-species community. When our LV-like model was 
applied to an in silico community of nasal species to determine the impact of environmental 
fluctuations, I find that nasal communities are generally robust against pH fluctuations and that, 
in this condition, facilitative interactions are a stabilizing force, and thus, selected for in in silico 
enrichment experiments.  
 
Overall, this thesis further corroborates the association of microbiota with URT diseases and 
treatment outcomes while also providing unique insight into their association with specific 
etiologies in childhood asthma. This thesis also provides a framework for developing models 
able to facilitate the development of future microbiota-based therapies while also determining 
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Chapter 1                                                           
The Upper Respiratory Tract  
 
Human gut and nasal microbiota have been shown to impact disease and infections outcomes 
of the upper respiratory tract (URT). In this Chapter, I will summarize what is known about each 
of these microbial communities and how aberrant microbiota composition associates with 
diseases of the upper respiratory tract. In the first section, I will describe the physiology and 
function of the nasal cavity, the general characteristics of the nasal microbiota environment, 
nasal microbiota composition over time, important species interactions, and the compositional 
shifts that occur during acute and chronic infections of the nasal cavity. The second section 
holds a similar structure, however, much of the focus is on the association between gut 
microbiota/microbiota-derived metabolites and childhood asthma.  
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1.1 Physiology and Function  
1.1.1 The Upper Respiratory Tract is Anatomically Complex and is Physiologically 
Important  
The upper respiratory tract (URT) includes the anterior nares, nasal cavity, sinuses, 
nasopharynx, Eustachian tubes, middle ear cavity, oral cavity, oropharynx, and larynx (1). The 
URT also contains the olfactory sensing system located at the roof of the nasal cavity (Figure 
1.1).  
 
Epithelial makeup and structure vary based on anatomical region, creating a diversity of 
ecological niches within the URT (1). In the anterior part of the nasal cavity (Figure 1.1 - from 
anterior to posterior), epithelial cells range from the keratinized epithelium of the anterior nares; 
to the stratified squamous cells without microvilli and the transitional epithelium with short 
microvilli immediately posterior of the nares; to the pseudostratified columnar epithelium 
(containing mucus-producing goblet cells) of the middle meatus (2–4). Moving to more posterior 
and cranial parts of the nasal cavity, the nasopharynx contains both keratinized and non-
keratinized stratified squamous epithelium and pseudostratified ciliated epithelia (5) and the 
sinuses are coated with ciliated columnar epithelium (6). Overall, columnar cells make up 70% 
of the epithelium (with microvilli) while 20-50% of cells contain mucus-clearing cilia and 5-15% 
of epithelia are mucus-producing goblet cells (7,8).  
 
Nasal mucosa lines the entire nasal cavity – from nostrils to pharynx – and is primarily 
comprised of water, glycoproteins, and ions (8). Its structure consists of two layers: the lower 
liquid layer and the upper, more viscous, gel layer that is principally composed of the 
glycoprotein, mucin (8). The glycoprotein composition of the mucus determines its viscosity and 
elasticity along with its adhesive properties (8,9). Mucus is produced by seromucous gland, 
goblet cells, mucosal tissue and tear fluid, and through the transudation of blood plasma (8).The 
Bowman’s gland, located in the olfactory epithelium, also produces mucus which protects the 
olfactory epithelial from desiccation while also dissolving odor-containing gases (10–12). These 
glands are also responsible for producing binding proteins that aid in the transport of odors to 





Figure 1.1 Anatomy and epithelial makeup of the nasal cavity. 
 
1.1.2 The URT Filters Inhaled Air and is a First-line Defense Against Harmful 
Particulate and Microbes  
Around 12,000 liters of air pass through the nasal passage per day (8). The URT is the primary 
interface between the external environment and the human host; filtering, humidifying and 
warming inhaled air (10,13).  As the first barrier to the internal body, the nasal passage protects 
the respiratory system from harmful environmental particulate, pollutants and microorganisms 
(8,14). The amount of inhaled gas that reaches lung alveoli is significantly reduced during nasal 
breathing (0.9%) compared to mouth breathing (6-10%)(15), further proving its importance as a 
first-line defense and filtration system.  
 
The nasal cavity removes harmful particulate and pathogens by a number of mechanisms. 
Large particles are trapped by epithelial cells in the anterior nares by vibrissae (hair) and 
sebaceous gland secretions while smaller particles are captured by the mucus membrane (2–
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4,16). Nasal mucosa is the principal mechanism for clearance by way of ciliary beating (8). 
Meanwhile, compounds contained within the mucosal layer act as antimicrobials. Broad 
spectrum defenses against pathogenic bacteria and viruses include nitric oxide (17), lysozyme, 
lactoferrin and oligosaccharides (18). Interestingly, the presence of nitric oxide also increases 
ciliary beat frequency, leading to more mucus movement and improved clearing (19). Mucus 
also contains a high concentration of enzymes – particularly cytochrome P450 enzymes – 
responsible for the oxidation of steroids, fatty acids, and xenobiotics (8). These enzymes are 
also crucial for drug metabolism, the clearance of various compounds, and are important for the 
biosynthesis of defensive compounds, fatty acids and hormones (8).   
 
Immune cell and immune-derived compounds are also found in high concentrations in the nasal 
mucosa (20). Immune cells found in the subepithelial tissue of the nasal cavity and sinuses 
include neutrophil granulocytes, monocytes and macrophages (8). The immune-derived 
compounds, immunoglobins G (IgG) and A (IgA), are also found in the nasal mucus. In fact, IgA 
is thought to represent up to 50% of the total protein found in nasal secretions (20).  
 
1.2 Human Microbiota and the Upper Respiratory Tract  
The term ‘microbiota’ refers to all microorganisms specific to an ecological niche (21). The 
human body is home to a diverse community of microbes which exert a major impact on host 
health, metabolism and immune function (22,23). Human microbiota also display significant 
variation based on time/age, geographic location, intra-specific body site, and between 
individuals (22,23). Commensal microbiota promote the development and maturation of the 
immune system, reinforce the epithelial barrier, contribute to nutrient metabolism, and inhibit 
inflammation (24–30). The structure and function of such microbial communities are impacted 
by both genetic and environmental factors. How these factors affect community composition and 
how the resulting microbiota affects health outcomes are largely unknown. However, one 
characteristic that has been consistently correlated with better health and protection against 
both acute and chronic diseases is high microbial diversity (24,31,32). In turn, dysbiosis in any 
ecological niche of the human host has been associated with a breadth of disease states 





1.2.1 Nasal Cavity Microbiota  
The nasal cavity is spatially and environmentally heterogenous, creating many ecological niches 
capable of supporting a diverse microbial community. The nasal microbiome consists of both 
transient microorganisms introduced by the external environment and resident colonizers 
(1,34,35). Although microbial composition can vary widely, current research has indicated that 
nasal microbiota remain relatively stable over time (2,24,36). As such, dysbiosis of the nasal 
microbiome has been associated with a number of upper respiratory tract diseases (34,35,37).  
 
1.2.1.1 Nutrient Environment of the Nasal Passage for its Inhabiting Microbes  
Unlike gut microbiota, the microbiota of the upper respiratory tract are not provided with 
digested food sources and rely on epithelial cells of the nasal cavity as their sole source of 
nutrients (38). The nasal cavity is generally nutrient-poor and contains low levels of potassium, 
magnesium, phosphates, sugars, amino acids, and other essential building blocks (38,39). The 
nasal environment also contains low concentrations of essential metals including zinc, iron and 
manganese (40) thanks to the sequestration of such metals by human lactoferrin and 
calprotectin (40).  
 
To survive in this harsh landscape, bacteria must possess a metabolically diverse genetic 
repertoire. Common colonizers of the nose are known to produce a range of proteases with 
varying specificities (40–45). For example, metabolomic and genomic analyses reveal that 
many nasal bacteria can produce enzymes that break down human proteins including sialic acid 
(found on the surface of eukaryotic cells), albumin, lactoferrin, mucins, cytokeratin 10 and 
hemoglobin (40,41,46).  
 
Nasal bacteria must also withstand mucosal clearance, making epithelial attachment imperative 
to survival. Species most often specialize in binding either keratinized or non-keratinized cells 
(47–50). However, some species (e.g. S. aureus), are found attached to both cell types (47–50). 
Like many gram-positive bacteria, S. aureus produces teichoic acids and glycopolymers as part 
of their cell wall; two of the many compounds that allow for epithelial cell adhesion (49,51–54).  
 
The organizational patterns of bacterial growth in the nasal cavity are not currently known; 
whether they grow in biofilm structures, clusters, or as dispersed cells is up for conjecture. 
Some evidence indicates that Propionibacterium-produced coporphyrin III induces S. aureus 
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biofilm formation (55). However, many speculate that nasal bacteria are more likely to grow in 
small clusters or as dispersed cells (51).   
 
1.2.1.2 Nasal Microbiota in Health  
The healthy nasal microbiome is colonized by both commensal and opportunistic pathogens 
(referred to throughout as pathobionts). The three most common phyla found to colonize the 
nasal cavity include Actinobacteria, Firmicutes and Proteobacteria (56). The microbial 
community of the nasal microbiome most closely resembles that of the skin and oral cavity and 
is considered a bridge between the two environments (56,57). However, there are some distinct 
differences. For instance, Streptococcus spp. are highly abundant in the oral cavity but are less 
prevalent in the nose (58) while coagulase-negative S. aureus (CoNS) are seen in high 
abundance on the skin but are only found in the nasal cavity of some individuals (59). Yet, 
Staphylococcus epidermidis consistently colonizes both the skin and the nose of most 
individuals (59).  
 
Only a small number of genera and species account for the majority of taxa; both in abundance 
and prevalence (Figure 1.2) (60). At the species level, Cutibacterium acnes (formerly 
Propionibacterium), Staphylococcus aureus, Staphylococcus epidermidis, and Corynebacterium 
spp. are commonly identified in the healthy nasal microbiome (24,61–63). A study investigating 
nasal microbiota composition differences between monozygotic and dizygotic twins identified 7 
distinct community state-types which were defined based on the dominant species: S. aureus, 
Enterobacteriaceae (Escherichia coli, Proteus spp., Klebsiella spp., etc.), S. epidermidis, 
Propionibacterium spp., Corynebacterium spp., Moraxella spp., or Dolosigranulum spp. (64,65). 
This study also determined that host genetics do not significantly impact microbial community 
structure of the nasal cavity, however, genetics and sex did positively correlate with nasal 
bacterial density (65).  
 
While microbiota composition can vary between individuals and over time, a breadth of 
community compositions contribute to human health suggesting that microbial function, rather 
than structure, may be the more important consideration (24,66). Notably, nasal microbiota are 
thought to shape olfactory function (67). In an in vivo study, germ-free mice had thinner olfactory 





Figure 1.2. A small number of genera and species account for the majority of taxa in the nares (Escapa et al., 
2018). 
 
and abundance of certain genera, including Moraxella and Staphylococcus, are associated with 
olfactory function (67,68). Microbial composition is also predictive of surgery outcomes. Patients 
with a more diverse nasal community, particularly the middle meatus, were found to have better 
postsurgical outcomes after nasal endoscopy (69). Overall, a stable and diverse nasal 
microbiome has a protective effect against upper respiratory complications and diseases 
(13,70).  
 
Until recently, the lung was thought to be devoid of resident microbes. Yet, recent efforts to 
characterize this environment have discovered a resident microbial community. The 
composition of lung microbiota is determined by regional conditions (pH, humidity, oxygen, 
nutrients) and is heavily influenced by microbial immigration via aspiration from the upper 
airways (71).  In one study comparing the microbial composition of the upper aerodigestive 
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tract, lung microbiota were distinct from that of the oral, nasal, and gastric communities but was 
most similar to the oral cavity in composition (72). The lung microbiome is not the focus of this 
research, however, it is important to note that this microbial community also influences upper 
respiratory disease onset and outcomes.   
 
1.2.1.3 Nasal Microbiota of Healthy Individuals Over Time  
Microbial composition varies over the lifespan of an individual. At birth, nasal microbiota 
resemble that of the maternal vaginal and skin microbiota (13,73). Although results have varied 
between studies, a U.S.-based study identified Propionibacterium, Lactobacillus, Streptococcus, 
Staphylococcus, and Corynebacterium as the most prevalent taxa within the first 24-hours of life 
(74,75). The nasal microbiota then begins to differentiate as early as the first week of life (74); a 
compositional shift likely driven by the maturation of the immune system (76). In the proceeding 
weeks, the relative abundance of Propionibacterium and Lactobacillus decreases while 
Moraxella, Staphylococcus and Corynebacterium increase over time (74,75). Some studies 
have also found Haemophilus and Dolosigranulum to be common nasal residents (77–79).  
 
As the nasal microbiome begins to settle into its adult form, microbial density decreases while 
diversity increases (13,80–82).  The anterior nares (AN) are primarily colonized by 
Actinobacteria and Firmicutes along with low levels of Bacteroidetes (13,67,82–85). The AN 
experiences lower microbial diversity, a greater abundance of Firmicutes and Actinobacteria, 
and fewer Proteobacteria compared to more distal regions of the nasal cavity (middle meatus, 
sphenoethmoidal recess)(86). However, site-specific differences become less distinct 
throughout aging (1). Compositional shifts occur during middle age (40-65 years of age). The 
adult nasal microbiome is dominated by Corynebacterium spp., Cutibacterium spp., and 
Staphylococcus spp. genera whereas the microbiome of the elderly shifts towards an 
oropharynx-like profile (81,87). This process is thought to occur due to immune-senescence and 
an increase in inflammatory markers which, in turn, leads to significant species loss (87). 
Currently, there are very few longitudinal studies investigating compositional shifts in the elderly. 
Several cross-sectional studies have been conducted but conclusions from these studies vary 




1.2.1.4 Early-life Factors, Lifestyle, and the External Environment Impact Nasal 
Microbiota 
Early-life factors that can influence community composition are delivery method at birth 
(Cesarean section or vaginal) and breastfeeding. Children born by C-section show a delay in 
nasal microbiota development primarily marked by a reduction in Dolosigranulum and 
Corynebacterium species (90). However, another study observed a significant increase in 
community richness in C-section infants (77). In breastfed infants, Staphylococcus and 
Corynebacterium species are enriched at 6-12 weeks of age (79,91). Yet, a contrasting study 
found that strictly breastfed infants had a higher abundance of Dolosigranulum and 
Corynebacterium while formula-fed infants carried a higher abundance of Staphylococcus (70). 
Another study also found that breastfed infants had a higher abundance of Moraxella and 
Corynebacterium/Dolosigranulum and were less likely to report respiratory infections (70). 
Interestingly, any distinction in composition between breastfed and formula-fed infants was 
ameliorated by 6 months of age (70). However, the succession of colonization during early life 
may impact immune maturation and is thought to dictate the stability of the microbiome over the 
first few years of life (70,73,74). 
 
Immunization and antibiotic use have profound effects on nasal microbiota composition. In a 
study by Tarabachi and colleagues (2015), live attenuated influenza vaccines led to significant 
changes in structure and diversity along with increases in the relative abundance of 
Staphylococcus and Bacteroides genera (92)). Similarly, antibiotic use is known to significantly 
alter nasal microbiota, decrease diversity and evenness, and lead to an increased abundance of 
antibiotic-resistant microbes (93,94). Furthermore, children that were given two or more doses 
of antibiotics before the age of 1 had significantly lower abundances of Moraxella and an 
increased risk of developing asthma (95).  
 
Inhalants impact nasal microbiota with habitual smoking being the most well characterized. 
Smoking significantly impacts community composition (96) by decreasing alpha diversity (64) 
and can result in a higher frequency, and greater severity, of chronic rhinosinusitis (CRS) 
infections (30,36,97). In one study on sinus microbiota, Brook and Hausfeld (2015) found that 
smokers were more likely to be colonized by S. aureus, particularly methicillin-resistant S. 
aureus (MRSA), along with a significant number of beta-lactamase producing gram negative 




Significant seasonal changes have also been observed in more temperate zones (21,91,98–
101). In one study by Camarinha-Silva and colleagues, seasonal shifts were observed over a 
15-month period in an inter-dependent manner (100). The most drastic shifts occurred in the 
relative abundance of Propionibacterium acnes and Staphylococcus epidermidis and while 
community composition was highly variable over time, species considered core members of the 
microbiome remained stable. 
 
While host-derived traits, such as genetics and sex, do impact nasal bacterial density, many 
studies indicate that nasal microbiota is an environmentally derived trait and a number of 
environmental factors –temperature, humidity, pollen, chemicals, etc. – are able to drive 
community composition (64,65,100,102,103). Despite this evidence, very few studies have 
looked at the effect of individual environmental factors on nasal microbiota structure and 
function. 
 
1.2.1.5 Species Interactions Impact the Structure of Nasal Microbiota   
In addition to environmental factors, species interactions have a considerable impact on 
microbial community outcomes. In microbial ecology, much debate has transpired over the 
extent to which species interactions are positive (facilitative, synergistic, mutualistic, etc.) or 
negative (competition, direct inhibition), and how much such interactions contribute to the co-
existence of species within an ecological niche (1,104). For an overview of the known 
interactions between species in the nasal cavity, see Figure 1.3 (1).  
 
Studies on species interactions amongst nasal microbiota have focused heavily on interactions 
with pathobionts due to their strong associations with upper respiratory and more systemic 
diseases. In this research, we are particularly interested in interactions between S. aureus and 
other nasal microbiota. Nasal S. aureus colonization increases the risk for Staphylococcal 
infections and is of medical concern due to the alarming increase in antibiotic-resistant strains. 
As such, novel therapies capable of preventing S. aureus colonization and/or S. aureus-related 
infections are greatly needed. Understanding the interaction dynamics of microbiota, particularly 
competition, can provide the knowledge necessary for the elimination of such infectious agents 
and has significant implications for future therapies (1). Interactions between S. aureus and 
other nasal microbiota are well characterized, and several species are shown to inhibit S. 
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aureus colonization, thus, making S. aureus a good candidate for developing future therapy 
strategies, such as microbiota-based treatments.   
 
Many factors effect S. aureus colonization including genetics, the environment and nasal 
microbiota (64). While host genetic polymorphisms in several immune-associated genes have 
been associated with higher S. aureus colonization rates (64,105), it is widely thought that 
environmental factors (89,94) and the resident microbiota have a greater impact on colonization 
success (64,65). A significant body of work has shown that commensals, like Corynebacterium, 
interact with S. aureus in a species- and strain-specific manner (2,106,107). Corynebacterium 
pseudodiphtheriticum has been negatively associated with a S. aureus carrier status while co-
cultivation of S. aureus with Corynebacterium accolens results in a mutualistic increase in both 
cell types (2). Interestingly, cell-free spent media derived from Corynebacterium striatum has 
been shown to shift S. aureus into a more commensal-like state; down-regulating genes 
involved in colonization and/or virulence (1,64,106,108). Comparative genomic work also 
indicate that S. aureus and C. striatum compete for essential nutrients such as iron and 
methionine (106). The commensal species Dolosigranulum pigrum has also been negatively 
correlated with S. aureus colonization and positively correlated with several Corynebacterium 
species which are thought to release essential nutrients required by this highly auxotrophic 
commensal (60,70,73,79,80,109–112).   
 
Studies have also identified negative correlations between S. aureus and other Staphylococcus 
species, particularly between S. epidermidis and S. aureus (36,97). In vitro and in vivo studies 
have found direct inhibition of S. aureus by serine protease (Esp)-producing strains of S. 
epidermidis (97); an enzyme that binds and degrades structural proteins essential in S. aureus 
biofilms (113). A pheromone produced by S. epidermidis via agr-system quorum sensing has 
also been identified as effective against S. aureus by inhibiting the expression of several 
virulence factors (114).  
 
Methicillin-resistant S. aureus (MRSA) is of particular medical concern and much attention has 
been paid to nasal microbiota that are able to inhibit MRSA colonization. In a cross-sectional 
study by Bessesen and colleagues (2015), Streptococcus mitis and Lactobacillus gasseri were 
negatively associated with MRSA colonization and microbial diversity was correlated MRSA-
carrier status (115). Like many species of Streptococcus, S. mitis was found to inhibit MRSA 
growth by producing hydrogen peroxide (115). Similarly, Streptococcus pneumoniae is 
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negatively correlated with S. aureus (116–124) and has been shown to kill S. aureus by 
converting hydrogen peroxide into a hydroxyl radical (125).  
 
 
Figure 1.3. Influence of nasal microbial community members on each other (Kumpitsch et al., 2019). 
 
Beyond bacterial interactions, bacterial-viral and bacterial-fungal interactions have been 
documented in the nasal cavity, although cross-kingdom interactions are generally 
understudied. Acute viral infections effect upper respiratory microbiota by altering the 
community composition, bacterial burden, and Shannon diversity (126–129). These 
modifications are commonly accompanied by secondary bacterial infections and an 
exacerbation of disease symptoms (127,128). Viral infections have also been shown to increase 
pathogen abundance while simultaneously enhancing their epithelial adhesion properties (130–
138). Specifically, strong associations have been observed between S. aureus and the influenza 
virus (139). Yet, other work has alluded to a protective role for S. aureus during viral infections 
(140). In one study, S. aureus colonization significantly reduced influenza-induced lung damage 
and decreased mortality rates in a murine model (140). Conversely, certain species of bacteria 
have been shown to impact viral infectivity and influence the host response to viral invasion 
(140–142). In two such studies, children colonized with S. pneumoniae were more likely to 
experience subsequent acute respiratory illness (141,142).  
 
Interactions between bacteria and fungi have also been described, yet little is known about the 
specific interactions that occur in the nasal cavity. These microorganisms interact in a multitude 
of ways: they exchange and convert metabolites, influence cell adhesion, create new niches 
and modulate the tolerogenic immune response (143). In an environment with unrestricted 
levels of tryptophan, Lactobacilli increase host resistance against Candida infections by 
activating xenobiotic production and type 3 innate lymphocytes (143,144). Candida host 
resistance also occurs through commensal-induced IL-22 cytokine production (143,144). 
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Significant alterations to the nasal microbial community have been detected in Candida-related 
diseases. In a study on fungal rhinosinusitis, the microbial diversity of the middle meatus was 
decreased and a distinct species distribution – lacking in Corynebacterium and Fusobacterium 
with increased Haemophilus abundance – was observed in infected individuals compared to 
healthy controls (143). On the other hand, fungal colonization in the nose can act as a facilitator 
of bacterial invasion and disease. For instance, S. aureus can bind to the hyphal form of 
Candida albicans and invade damaged epithelial cells using hyphal-induced breaks in the cell 
wall (145).  
 
As illustrated, the nasal cavity is host to a dynamic community of bacteria that interact in diverse 
ways. Knowing how individual species interact with S. aureus is beneficial from a mechanistic 
standpoint, however, to fully comprehend how nasal microbiota influence S. aureus 
colonization, community-level investigations are needed.  
 
1.2.1.6 Nasal Microbiota and Upper Respiratory Disease 
Chronic and acute respiratory diseases remain the leading cause of death worldwide (101). 
Evidence shows that airway microbiota are able to modulate the local immune response and 
influence susceptibility to – and severity of – upper respiratory infections (URIs) (146) and 
chronic diseases, such as asthma (95,147)). During infection, microbial burden increases, 
diversity decreases, and drastic shifts in community composition occur (116,123,124). Whether 
these alterations are an effect of the infection/disease or whether nasal microbiota directly 
impact disease susceptibility and/or severity has not been clearly established.    
 
Results from longitudinal and cross-sectional studies have alluded to the complex interplay 
between nasal microbiota and upper respiratory disease.  Strong correlations between 
Moraxella-dominant nasal microbiota profiles and acute respiratory infections have been 
identified (146) while asthma and bronchiolitis have been correlated with Moraxella-sparse 
microbial communities (73,147–149). A longitudinal study on acute respiratory infection (ARI) 
susceptibility in the first years of life found that the incidence of ARIs was the greatest in 
children colonized early on with a Moraxella-dominant profile while a Corynebacteriaceae-
dominant profile had a protective effect (146). Similar conclusions were made by another study 
looking at nasal microbial composition during an upper respiratory viral infection (150). Yet, 
other studies have suggested that Moraxella-sparse profiles are associated with a significantly 
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higher risk of asthma (147) and acute respiratory infections (73), including bronchiolitis (149). 
Hasegawa (2017), and others, have also observed strong correlations between 
Corynebacterium/Dolosigranulum-enriched profiles and a lower incidence of acute infection 
(73,74,149). These data indicate that certain nasal microbiota profiles may protect against 
certain upper respiratory diseases while simultaneously increasing one’s risk for others.  
 
Staphylococcus aureus-enriched profiles have been correlated with several respiratory diseases 
including asthma (64,151), pneumonia (152), chronic rhinosinusitis (21) and respiratory viral 
infections (77). However, several studies have shown negative correlations between S. aureus 
and acute respiratory disease (74,79). Specifically, children hospitalized for respiratory syncytial 
virus (RSV) had Haemophilus influenzae- and Streptococcus-enriched profiles which were 
negatively correlated with S. aureus colonization (80).   
 
These results are yet another illustration of the complex interplay between nasal species and 
upper respiratory disease. While species correlations may not be consistent across disease-
states, many studies have found consistent correlations between the high abundance of several 
pathobionts – S. pneumoniae, H. influenzae, and S. aureus – and lower levels of diversity and 
decreased levels of commensals (115,153,154). Broadly, this implies that general dysbiosis in 
nasal microbiota can lead to an increased risk for upper respiratory disease (64,93,155). 
 
1.2.2 Gut Microbiota 
1.2.2.1 Gut Microbiota of Healthy Individuals Over Time  
Since the inception of gut microbiome research, more than 20,000 journal articles have been 
published on the topic (126). This staggering statistic demonstrates the broad interest in this 
microbial system, but also exemplifies the importance of this microbial community in human 
health and disease. Like the nasal microbiome, the gut microbiome comprises of both resident 
and transient microorganisms with colonization being largely determined by the local 
environmental conditions (156–158). For an overview of gut microbiota composition over time, 
see Figure 1.4 (159).  
 
The first stages of microbial exposure/colonization ultimately determine the composition and 
succession of the infant’s microbiota and influences overall metabolism and immune modulation 
(160,161). Between birth and age 3, the infant microbiota changes drastically due to its constant 
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exposure to novel environmental/maternal microbes and food/animal-born antigens. By age 3, 
these fluctuations diminish as the microbiota composition settles into its adult-like state (162). 
Early life factors such as birth method (30,163), breastfeeding (164,165), use of probiotics 
(166,167) and antibiotic exposure (168,169) have been shown to influence early-life microbiota 
composition. Gut microbiota composition in early life is dominated by Bifidobacterium and 
Bacteroides species in vaginally-born and breast-fed infants; two species underrepresented in 
infants born by cesarean section (C-section) and/or were predominantly formula-fed in early life 
(30,163,165). These species are considered hallmarks of a healthy infant microbiota due to their 
well-characterized role as protective agents against disease later in life (170). Alternatively, 
infants born by C-section had an enrichment in pathobionts including Haemophilus spp., 
Enterobacter cancerogenus/E. hormaechei, Veillonella dispar/V. parvula, and Staphylococcus 
species (76,171). In one study, this microbial profile persisted throughout the first year of life 
and was significantly associated with the overall infectious disease burden of infants (171).  
 
In the adult microbiome, two phyla – Bacteroidetes and Firmicutes – constitute the majority of 
the composition (56,172). Studies characterizing gut microbiota in relation to specific diseases 
often focus on the Firmicutes:Bacteriodetes ratio, yet evidence from the Human Microbiome 
Consortium shows that this ratio can vary by over an order of magnitude between individuals 
(56). Hence, some have looked beyond species composition to the core community function. 
The functional profile of microbiota is established early on in life (173) and metabolic pathways 
are largely conserved despite large compositional variation (56,172,174,175). Core to this 
function are common gene families and regulatory pathways that are broadly categorized as 
either housekeeping or body-site specific functions (176,177). In the gut, the specific functions 
include production of short chain fatty acids (SCFAs), lipopolysaccharides, vitamins and 
essential amino acids, and the degradation of glycoaminoglycans (172,178–180). Thus, 
significant perturbations that alter community composition can, in turn, impact microbial 
community function and ultimately, overall health.  
 
A range of genetic and environmental factors can contribute to, and alter, microbiota 
composition. While host genetics can impact species-species and species-host dynamics in the 
gut, the greatest impact on microbiota is derived from exogenous sources (181,182). Yet, the 
majority of observed inter-individual variation in gut composition cannot be explained by either 
of these factors, leading researchers to speculate about unknown stochastic elements such as 
priority effect (161). In one study, mice were inoculated with 4 bacterial strains in various 
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sequence to determine how colonization order impacted the microbial composition. The authors 
found that colonization order influenced final community assemblies and determined the overall 
colonization success of certain strains (161).  
 
To add to this convolution, other evidence suggests that microbiota are affected by other host 
characteristics including ethnicity, geographic location, and or/ socioeconomic status (182–185). 
A survey conducted as part of the Healthy Life in an Urban Setting (HELIUS) cross-population 
study found that ethnic origin was the strongest determinant of fecal microbiota composition 
(184,186). Yet, other studies have contradicted such results. In an Israeli study, gut microbiota 
composition was more strongly influenced by environment – rather than genetics – which 
accounted for 20% of the total variance (183). These data illustrate the many challenges faced 
when attempting to define the composition of “healthy microbiota”. Thus, further research is 
needed to identify baseline microbiota profiles for healthy individuals across geographic 
locations (183).  
 
Despite difficulties intrinsic to defining healthy microbiota composition, broad microbial 
community characteristics have been identified in association with improved health (31). Like 
nasal microbiota, higher microbial diversity equates to greater temporal stability and increased 
resiliency (187,188) while decreases in diversity and dysbiosis are frequently observed in 
disease states including irritable bowel disease (189), type-1 and type-2 diabetes (173,190), 
obesity (191), and chronic diseases of the airway (192).  
 
1.2.2.2 Gut Microbiota Influence Disease-state in Subjects at Risk for Developing 
Asthma 
Asthma is a chronic respiratory condition that is marked by bronchial spasms which result in 
airway constriction and breathing difficulties (193–196). Airway constriction is a direct result of a 
dysregulated pro-inflammatory response which can be triggered by allergens, respiratory 
infections, exercise and/or medications (193–195). This pro-inflammatory response involves the 
infiltration of several different immune cell-types – eosinophils, lymphocytes, mast cells, and 
phagocytes – that release various inflammatory mediators including cytokines, chemokines, 
growth factors and eicosanoids (194,197–199). This, in turn, causes bronchospasms and 
epithelial damage, creating a cycle of chronic inflammation (197). Several asthma endotypes 
have been described based on the underlying molecular mechanisms involved. While allergic 




Figure 1.4. Age-related changes in the human gut microbial ecosystem and potential factors that affect 
microbiota composition at different stages of life (Ravinder et al., 2018). 
 
helper 2 (Th2) immune response, IgE production and eosinophil recruitment to the lungs 
(Figure 1.5), other non-atopic phenotypes exist which are generally defined by a neutrophilic 
immune response and Th1/Th17 cell inflammation (200–202) (Figure 1.6). Atopy can also exist 
among non-asthmatics, suggesting only a weak link between atopy and asthma. Considering 
this heterogeneity, medical professionals have proposed diagnostics in which asthma and atopy 
are analyzed as separate outcomes (202,203). In fact, several recent studies have outline both 
clinical characteristics (204) and genetic markers (205) that could be used to decipher the 
various asthma endotypes.  
 
Core to this complexity is an interplay between the host, the immune system and the resident 
microbes. Gut microbiota are important in the maturation and modulation of the immune system 
and are shown to affect immune response and inflammation at distal body sites, including the 
lung. In fact, diseases of the gastrointestinal and respiratory tracts are frequently observed in 
tandem (196,206,207) and evidence indicates that gut microbiota may directly affect respiratory 
disease onset and development (208–211). For an overview of asthma-associated microbiota, 




Figure 1.5. T-helper cell 2 (Th2) immune response to allergens and infections. In this immune response, 
activated Th2 cells trigger B cell IgE antibody production via IL-4 signaling. Th-2 produced IL-4 and IL-13 cytokines 
also induce smooth muscle contractions of the lung. This pathway, in turn, causes the degranulation of mast cells, 
leading to eosinophil recruitment to the lung.   
 
Like other diseases, early-life environmental and microbial exposures can impact asthma-
related outcomes. High microbial diversity, breastfeeding, and the presence of beneficial 
bacteria are shown to protect against the onset of asthma and allergic diseases (212–214). 
Underlying these benefits is a properly modulated immune system. Regulatory T-cells (Tregs) 
play a fundamental role in maintaining immune tolerance for self-antigens and commensal 
microbiota, and in turn, these microbes have been shown to induce Treg production and alter 
susceptibility to allergic diseases (29,215,216). Bacteria-associated elements such as short 
chain fatty acids (SCFAs) and cell-surface lipopolysaccharides (LPS) can also impact immune 





Figure 1.6. T-helper cell 1 (Th1) and T-helper cell 17 (Th17) immune response to aberrant airway microbiota 
and pollutants. In this immune response, Th1/Th17 are activated by monocytes/macrophages recruited to the lung. 
Activation of both cell-types are then continuously re-activated by cytokines produced by each cell type.The cytokine 
IFN-γ also induces smooth muscle contractions of the lung. Monocytes and macrophages also recruit neutrophils to 
lung.  
 
A study on preschool children found evidence for general gut dysbiosis amongst children 
diagnosed with asthma (219). Specifically, profiles reduced in Lachnospira and increased in 
Clostridium spp. were associated with asthma. Comparable work in infants and adults 
corroborates this association between Clostridium species and asthma development; 
particularly, Clostridium difficile (196,220). One such study also found increases in Eggerthella 
lenta and a significantly decreased abundance in Faecalibacterium prausnitzii, Sutterella 
wadsworthensis, and Bacteroides stercoris (196,221). Similarly, a study conducted by Arrieta 
and colleagues found that infants with asthma had a significant reduction in Lachnospira, 
Veillonella, Faecalibacterium and Rothia species along with a reduction in the SCFA, acetate 
(196,222). Increases in acetate have been observed in tandem with enhanced Treg cell 
numbers and a decrease in asthma and allergic diseases suggesting a functional role for these 
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species (223). Yet, another U.S. study on neonates found that children at the highest risk of 
developing atopy and asthma had the lower relative abundance of Bifidobacteria, Akkermansia 
and Faecalibacterium genera (214). Akkermansia is also negatively correlated with more severe 
asthma endotypes (224,225).  
 
An increase in Bifidobacterium and Lactobacillus species have also been shown to play a 
protective role in asthma and allergic disease (196,226–228). The colonization of germ-free 
mice with a mix of Lactobacillus (L. rhamnosus and L. casei) and Bifidobacterium (B. breve) led 
to significantly lower levels of IgE and IgG; increased production of IgA; an enhanced gut 
epithelial barrier and reduced allergic sensitization in response to allergen challenge (226). 
Given as a probiotic, Lactobacillus fermentum and/or L. paracasei were likewise shown to lower 
the severity of asthma in children between 6 and 18 years of age (229). Taken together these 
data demonstrate the important role that commensal gut microbiota play in not only preventing 
asthma onset, but also in reducing the severity of asthma-related symptoms.   
 
While previous studies can agree on the association between some gut microbiota and 
asthma/atopy, many relationships remain enigmatic and conflicting. For example, results have 
varied regarding Bacteroides species. Wang and colleagues found a decreased abundance of 
Bacteroides stercoris while another study by Arrieta and colleagues observed a higher relative 
abundance of Streptococcus and Bacteroides species and a lower abundance of 
Bifidobacterium and Ruminococcus gnavus in children at higher risk of developing atopy and 
wheeze at age five (230). These data exemplify the complex interplay between gut microbiota 
and asthma and demonstrate the importance of identifying asthma-associated taxa at the 
species level in addition to deciphering gut microbiota composition based on specific endotypes.  
As such, patients with asthma marked with a predominantly neutrophilic immune response have 
a unique gut microbiota profile compared to patients with eosinophilic (atopic) asthma. Patients 
with a neutrophilic-dominant immune response have lower bacterial diversity and an enrichment 
of Haemophilus and Moraxella species along with a reduction in Streptococcus, Gemella, and 
Porphyromonas taxa in the lung (224,231–234) while another study found an increased 
abundance of Fusobacterium, Porphyromonas, and the Sphingomonodaceae family along with 
a decrease in the Mogibacteriaceae family and Lactobacillus order in atopic (eosinophilic) 
asthma (235). Interestingly, patients with a predominantly neutrophilic immune response are 
also more likely to take high doses of inhaled corticosteroids (ICS) and have a more severe 
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disease endotype (224). This suggests that asthma therapies impact microbiota, and in turn, 
microbiota can impact treatment response.  
 
Patients taking ICS and oral glucocorticoids have an increased abundance in Proteobacteria 
and Pseudomonas and a decrease in Bacteroidetes, Fusobacteria and Prevotella in the lung 
(224,236). A complimentary study by Durack and colleagues (2017) investigated the lung 
microbiota of mild asthmatics not treated with ICS. In this study they found an enrichment in 
Haemophilus, Neisseria, Fusobacterium, Porphoryomonas and the Sphingomonodaceae family 
with a concurrent depletion in Lactobacillales and the Mogibacteriaceae family in patients with 
mild asthma (235). Whether microbiota composition is a result of the endotype and/or treatment 
type or if microbiota impact disease outcomes is not fully understood. However, some evidence 
points to a direct interaction between certain taxa and ICS treatment response/asthma 
endotype. Several studies in adults have identified an increased abundance of Haemophilus 
species in the airway of asthmatics (233–235,237–240), and in one study, mice chronically 
colonized with Haemophilus influenzae (lung) had a neutrophilic immune response and were 
more often steroid resistant (240). Since this study, work by Goleva and colleagues observed 
similar interactions between Haemophilus parainfluenzae and steroid response in the adult 
airway (239). Both studies suggest a role for Haemophilus species in treatment response in 
asthmatics, however, very few studies have looked at gut microbiota in association with 
treatment resistance. Further research is required to not only decipher asthma endotypes, but to 
also determine how endotype interacts with gut microbiota composition in asthma.  
 
1.2.2.3 Gut Metabolic Profiles are Altered in Asthmatics  
Metabolomics have been widely used to decipher asthma endotypes and many studies have 
been conducted using gut (241,242), airway (242,243) urine (242) and/or circulating blood 
metabolites (242,244). While the metabolites identified vary between studies and based on 
sampling site/technique, metabolic pathways consistently altered in asthma include amino acid, 
lipid, inflammation and immune response metabolism (245). A number of bacterial metabolites 
have an established association with asthma – either by protecting against or promoting atopy 
and asthma. Here, two major metabolic pathways historically associated with asthma will be 





Figure 1.7. Microbiota of the airway and the gut are associated with asthma. Patients with type 2 and non-type 2 
endotypes also show distinct airway microbiota profiles.  
 
 
Sphingolipids and sphingolipid metabolites have been studied across a breadth of conditions 
including neurological disorders, cancer, autoimmunity and pulmonary-related diseases (246). 
Sphingolipids are a class of lipids that are important structural components of membranes, 
lipoproteins and skin. They are also important cell signaling mediators. The notion that 
sphingolipids play a role in pulmonary disease was first proposed in the 1940s (247). Since 
then, sphingolipids and sphingolipid metabolites have been identified as potent mediators 
capable of modulating the immune response (248,249) and have been implicated in asthma and 
allergic diseases (246,250).  
 
Over one hundred genetic polymorphisms have been associated with an increased risk of 
asthma. Of these, the orosomucoid-like 3 gene (ORMDL3) is the most highly implicated (250). 
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This gene inhibits serine palmitoyltranferase, the rate-limiting step in sphingolipid biosynthesis 
(251). Mutations in this gene can lead to the impairment/dysregulation of sphingolipid synthesis 
which contributes to asthma pathogenesis (250–253). Further work is required to decipher the 
impact of specific mutations, however, recent efforts by Kim and colleagues (2020) 
demonstrated that mutations in the ORMDL3 gene result in a specific immune response 
depending on the location and the type of mutation that is present (251).   
 
To date, the most well-studied sphingolipid metabolite in association with asthma is 
sphingosine-1-phosphate (S1P)(253–261).  S1P is derived from the phosphorylation of 
sphingosine by two enzymes (SphK1 and SphK2) that are highly expressed in the lung (262). 
This metabolite is an important secondary messenger and/or extracellular ligand and 
accumulations of S1P have been associated with airway hyperresponsiveness and immune cell 
recruitment to the lung; specifically, IgE-mediated mast cell migration and degranulation 
(260,263,264).  In humans, S1P levels are increased after allergen challenge and mutations in 
the S1P receptor, S1P1, are overrepresented in adults with asthma (250,254,261).    
 
Sphingolipid metabolites also vary depending on the asthma endotype (265–268). In one study 
investigating differences in immune response and sphingolipid metabolites based on asthma 
severity/asthma control status found a strong correlation between immune response-type and 
ceramide levels in the serum of patients with severe, poorly controlled asthma (251). The 
metabolite ceramide is produced through de novo sphingolipid metabolism and/or the salvage 
pathway and is the central intermediate in sphingolipid synthesis; producing sphingomyelin or 
sphingosine (250,251). This study observed a strong neutrophilic immune response (measured 
by activated CD66+ neutrophils) along with increased levels of both ceramides (C16:0, C24:0) 
and sphingosine in patients with severe, poorly controlled, asthma endotypes (251). Conversely, 
patients with treatment-controlled asthma were more likely to have an eosinophilic immune 
response and higher levels of S1P (251).  
 
Sphingolipids are derived from host synthesis, diet or are produced by gut microbiota; 
particularly species in the phylum Bacteroidete (269). Specifically, Bacteroides fragilis produces 
sphingolipids that act as ligands for natural killer cells which promotes the proliferation and 
recruitment of this immune cell (170). In children, lower levels of fecal sphingolipids were 
associated with food allergies early on in life (270–272). Currently, the effect of Bacteroides-
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derived sphingolipids has only been observed in the colon (170) and further research is required 
to determine how these microbial-produced metabolites affect asthma.  
 
Histidine is an essential amino acid required for protein synthesis and is derived from 
proteolysis of endogenous protein and/or the hydrolysis of diet-derived proteins (273). Histidine 
can be catabolized into a variety of end-products depending on the tissue type (273). In 
enterochromaffin-like cells of the stomach, mast cells, basophils and in various regions of the 
brain, histidine can be decarboxylated into histamine by histidine decarboxylase (HDC)(274). 
Beyond mast cells, other innate and adaptive immune cells capable of expressing HDC (upon 
stimulation) include platelets, monocytes/macrophages, dendritic cells and neutrophils (274). 
Histamine production is induced by a range of cytokines and other immune mediating 
compounds and has a broad impact on host immunoregulatory responses (275,276). Four main 
G-coupled protein receptors (GCPRs) can bind to histamine with varying affinity, and histamine-
mediated immune responses differ depending on which receptors are bound (277,278).  
 
Not long after the discovery of histamine, it was discovered that histamine could cause 
anaphylaxis by inducing smooth muscle contraction and vasodilation (279). Since then, 
histamine’s role in allergic asthma has been well established (280). Although histamine is 
primarily produced by host-derived cells/tissues, histamine can also be produced by gut 
microbiota. Microbiota-produced histamine significantly impacts immune responses within the 
gut through a histamine type 2 receptor-mediated mechanism (281). In a study by Barcik and 
colleagues, several taxa overrepresented in asthmatics were shown to produce histamine in 
vitro including E. coli, Lactobacillus vaginalis, and Morganella morganii (281). In another study 
investigating the association between asthma, gut microbiota and serum metabolites found that 
taxa enriched in asthmatics were linked to shifts in serum metabolites and IgE response (244). 
Genes related to membrane trafficking, histidine metabolism and glycosaminoglycan 
degradation were upregulated in children with asthma (244). In a subsequent study by the same 
group, urine and plasma metabolic profiles were analyzed in correlation with IgE responses in 
children with asthma (242). Similarly, higher concentrations of histidine in plasma of asthmatics 
were observed while other differentially expressed metabolites varied based on the allergic 
reaction (food allergy vs. asthma) (242).   
 
Overall, a large body of work has described correlations between gut microbiota, microbiota-
derived metabolites and asthma. However, further research is required in order to decipher the 
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specific roles of these species/metabolites. Of particular importance is understanding how gut 
microbiota affect asthma severity and to what extent that they interfere with the efficacy of 
therapeutics.  
 
1.3 Conclusions  
Overall, diseases of the upper respiratory tract encompass a range of complex etiologies 
ranging from acute infections to chronic diseases of the lung and nasal cavity. This intrinsic 
complexity may cause many standard treatments to fail in the face of recalcitrant infections 
and/or severe forms of chronic disease. To improve the current standard of care, the factors and 
mechanisms at play in these hard-to-treat disease endotypes must be better understood.  
 
More recent research has looked beyond single species targets and/or immune modulation to 
more systemic approaches. This, in turn, has led many to investigate the role of microbiota in 
disease onset and management. In this pursuit, work has since demonstrated a significant 
association between gut, airway, and nasal microbiota and many upper respiratory diseases. 
However, our knowledge of what microbiota compositions are observed in what disease profiles 
is severely lacking. Yet, gaining these insights is crucial for the translation of such data into 
application.  
 
Microbiota-based therapies (MBTs) are a potentially viable therapy in the treatment of infections 
and chronic disease of the upper respiratory tract. Commonly used MBTs include probiotics, 
which are a specific combination of microbes known to beneficially alter the microbiome, and 
prebiotics, which include dietary changes used to promote the repopulation of beneficial 
bacteria. Two diseases that make good candidates for MBTs, and two that were the primary 
focus of this research, include Staphylococcus aureus infections of the nasal cavity, and 
childhood asthma. Moving forward, the challenge is understanding which species affect disease 
outcomes and how we can alter microbiota for therapeutic purposes.   
 
In this endeavor, mathematical modeling has proven to be a practical tool. Modeling allows for 
the translation of experimental data into application; enabling the prediction of not-yet-measured 
microbial community scenarios. While this tool ideally focuses only on the essential factors that 
allow one to accurately predict microbial community outcomes, oftentimes, the challenge lies in 
deciphering which parameters are minimally essential for such predictions. Thus, many turn to 
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one of the simplest models applied to microbial communities: the Lotka-Volterra (LV) pairwise 
model. This model only considers the fitness (i.e., growth) effects of individual species and 
assumes that the fitness of a species is the sum of its basal fitness (grown in isolation) and its 
fitness in the presence of both itself and other species in the environment. Thus, all interactions 
are typically expressed as a single equation where parameters vary over time to represent the 
influence of one species on another. While simple, it has proven to be a powerful tool for 
predicting microbial community outcomes in a variety of environmental conditions.  
 
Overall, to move the field of microbiota-based therapies forward would require: 1) the 
identification of microbiota profiles associated with upper respiratory tract disease, 2) the 
creation of a modeling framework capable of representing microbial dynamics, 3) the application 
of the knowledge derived from both study inquires and modeling outcomes to modify microbiota 
for therapeutic purposes. This thesis will focus on the first two steps of this proposed process: 
identification and modeling (Figure 1.8).  
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2.1 Introduction  
Asthma is a chronic disease of the lungs and one of the most prevalent chronic diseases of 
childhood.(282) Around half of children under age five years with asthma report having one or 
more asthma-related exacerbations over 12 months despite using prescribed therapies.(282) 
Asthma is a complex disease with a number of recognized subtypes.(202,283,284) Phenotypic 
differences, including response to asthma treatments, can be partly attributed to variation in 
inflammatory responses to exogenous or endogenous stimuli.(285,286) 
 
Maturation of the immune system is dependent on the microbiota in early life, and aberrant 
microbial composition has been associated with the onset of many autoimmune and 
inflammatory diseases, including asthma.(287) Longitudinal human studies have identified 
differences in early life gut microbiota composition in children who go on to develop asthma 
compared to healthy controls.(214,220,222,230) Less is known about the role of the microbiome 
in existing asthma, and while there is evidence linking airway microbiota and asthma 
morbidity(237,238,288–290), very few studies have investigated the gut microbiome in subjects 
with existing asthma.(281) 
 
Additionally, aberrant microbiota have been associated with treatment resistance(239). Inhaled 
corticosteroids (ICS) are the commonly prescribed maintenance therapy for asthma in children 
under the age of five years(291), but many children still experience exacerbations while using 
ICS. In fact, a large minority of adults with asthma respond sub-optimally to ICS(292,293) and 
pre-school age children also exhibit a differential response to medications including ICS.(286) 
The high proportion of non-response observed amongst ICS users has led researchers to look 
beyond factors such as adherence to identify other mechanisms at play.(294) One such study 
found that ICS-resistant adults had distinct airway microbiota including an increased abundance 
of Proteobacteria compared to ICS-sensitive subjects. Of note, Haemophilus parainfluenzae 
was overrepresented in the airways of ICS-resistant individuals and was shown to reduce 
responsiveness to corticosteroids while also inducing a pro-inflammatory response. (239) 
 
Using data from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)(295), we 
investigated the association between the gut microbiome/metabolome at age three years and 
asthma severity as defined by the proportion of quarterly questionnaires in which 
parents/guardians reported wheeze between ages three and five years in children with doctor-
diagnosed asthma. We also looked at ICS responsiveness in a subset of children with asthma 
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who used ICS the majority of the time. We hypothesize that differences in gut microbial 
compositions and metabolite concentrations are associated with both disease severity and ICS 
responsiveness in childhood asthma. To our knowledge, this is the first study to investigate the 
effects of gut microbiome and metabolome on disease severity and ICS responsiveness in 
childhood asthma.  
 
2.2 Results  
2.2.1 Asthma Cohort Subject Characteristics  
The VDAART study followed 806 children after birth. We analyzed a subset of 111 children with 
parent-reported doctor-diagnosed asthma (Asthma cohort, Figure 2.1). Fifty-five subjects 
reported wheeze ≥33% of the time (high wheeze), while 56 subjects reported wheeze <33% of 
the time (low wheeze). High wheeze subjects did not differ from low wheeze subjects on most 
baseline characteristics (Table 2-1). Study site was the only potential confounding factor 
significantly associated with wheeze (Table 2-1, p=0·0013) and was accordingly included as a 
covariate in models of key results. As expected, we found that high wheeze subjects were more 
likely to have used oral corticosteroids between the ages of three and five years (p=0·020). 
2.2.2 Differences in Microbial Diversity are Not Observed Based on Wheeze 
Proportion  
No significant differences in alpha diversity were observed at the species level based on 
wheeze proportion (Shannon index: Pearson’s r=-0·050, p=0·58; Simpson index: Pearson’s r=-
0·02, p=0·81) (Figure 2.2). Similarly, Bray-Curtis dissimilarity was not significantly associated 
with wheeze proportion at the species level (Adonis PERMANOVA p=0·74, Figure 2.2). Similar 
results were observed for alpha diversity after adjusting for study site (Shannon index adjusted 
linear regression beta= -0·095 (95% CI -0·27, 0·076), p=0·27; Simpson index adjusted linear 
regression beta= -0·40 (95% CI -1·44, 0·65), p=0·45). Likewise, beta diversity and wheeze 
proportion remained insignificant after adjusting for study site (Adonis PERMANOVA p=0·74).   
2.2.3 Gut Bacterial Taxa are Associated with Wheeze Proportion  
Because quantitative microbiome profiling, compared to traditional relative abundance profiling, 
may be preferable when seeking microbiota-disease associations(296), quantitative polymerase 
chain reaction (PCR) using universal 16S ribosomal RNA (rRNA) primers was used to estimate 













Figure 2.2. Scatterplot of fecal microbial alpha diversity and wheeze proportion in asthma cohort subjects 
and PCoA plot based on Bray-Curtis dissimilarity. No significant differences in alpha diversity were observed at 
the species level based on wheeze proportion (Shannon index Pearson rho = -0.05, p -value= 0.58; Simpson index 
Pearson rho = -0.02, p-value=0.81)(A). A PCoA with Bray-Curtis dissimilarity shows that subjects do not cluster 
based on wheeze proportion (Adonis PERMANOVA p-value = 0.74). High wheeze subjects are represented by green 
circles. Low wheeze subjects are represented by orange squares. Ellipses represent 95% confidence intervals 




Table 2-1 Subject characteristics by wheeze frequency for the asthma cohort. High wheeze subjects are those 
with reported wheeze at least 33% of the time and low wheeze subjects are those with reported wheeze less than 
33% of the time between ages 3 and 5 years. Mean (standard deviation) is shown for total IgE, body mass index 
(BMI), gestational age and early wheeze proportion; otherwise, numbers (%) are shown for each characteristic. 
 Categories All Children  (n = 111) 
High Wheeze  
(n = 56) 
Low Wheeze 
(n = 55) p-value 
Sex Female  46 (41.4) 25 (44.6) 21 (38.2) 0.62 
 Male  65 (58.6) 31 (55.4) 34 (61.8)  
      
Race/Ethnicity Black, non-Hispanic  71 (64.0) 37 (66.1) 34 (61.8) 0.59 
 White, non-Hispanic  18 (16.2) 10 (17.9) 8 (14.5)  
 Hispanic or Other  22 (19.8) 9 (16.1) 13 (23.6)  
      
Study Center  Boston  26 (23.4) 7 (12.5) 19 (34.5) 0.002† 
 San Diego  20 (18.0) 7 (12.5) 13 (23.6)  
 St. Louis 65 (58.6) 42 (75.0) 23 (41.8)  
      
Vitamin D Treatment  400 IU / day  58(52.3) 32 (57.1) 26 (47.3) 0.40 
 4,000 IU / day  53 (47.7) 24 (42.9) 29 (52.7)  
      
Maternal 3rd Trimester Vitamin D Levels (ng/mL)*** NA 28.7 +/- 15.0 28.7 +/- 15.2 28.7 +/- 15.0 0.99 
      
Total IgE (kU/L) (log scale)*/*** NA 4.1 +/- 1.6 4.4 +/- 1.7 3.9 +/- 1.4 0.15 
      
Food Sensitization**/*** No sensitization  47 (45.6) 22 (41.5) 25 (50.0) 0.51 
 Sensitization 56 (54.4) 31 (58.5) 25 (50.0)  
      
Environmental Sensitization**/*** No sensitization  59 (57.3) 26 (49.1) 33 (66.0) 0.12 
 Sensitization 44 (42.7) 27 (50.9) 17 (34.0)  
      
Early Wheeze Proportion (0-3 yrs.)* NA 0.36 +/- 0.3 0.41 +/- 0.3 0.31 +/- 0.2 0.06 
      
Body Mass Index (BMI)*/*** NA 16.7 +/- 1.7 16.4 +/- 1.9 16.9 +/- 1.6 0.10 
      
Maternal Asthma  No maternal asthma  52 (46.8) 22 (39.3) 30 (54.5) 0.16 
 Maternal asthma 59 (53.2) 34 (60.7) 25 (45.5)  
      
Maternal Education  Less than college grad  88 (79.3) 48 (85.7) 40 (72.7) 0.15 
 College grad or higher  23 (20.7) 8 (14.3) 15 (27.3)  
      
Birth Mode  Vaginal birth  77 (69.4) 36 (64.3) 41 (74.5) 0.33 
 C-section birth  34 (30.6) 20 (35.7) 14 (25.5)  
      
Gestational Age (Weeks)* NA 37.9 +/- 2.7 37.9 +/- 2.8 38.0 +/- 2.5 0.91 
      
Breastfeeding***  Formula given before 4 mo.  21 (20.4) 12 (23.5) 9 (17.3) 0.59 
 Strictly breastfed before 4 mo. 82 (79.6) 39 (76.5) 43 (82.7)  
      
Perinatal Antibiotic Exposure  No antibiotic exposure  48 (43.2) 23 (41.1) 25 (45.5) 0.78 
 Antibiotic exposure 63 (56.8) 33 (58.9) 30 (54.5)  
      
Oral Steroid Use Between Age 3 and 5 Years*** No OCS use   71 (71.0) 34 (60.7) 37 (84.1) 0.02† 
 OCS use 29 (29.0) 22 (39.3) 7 (15.9)  
      
Household Dog*** No dog  90 (82.6) 45 (80.4) 45 (84.9) 0.71 
 Dog  19 (17.4) 11 (19.6) 8 (15.1)  
      
Household Cat***  No cat  98 (90.7) 53 (96.4) 45 (38.2) 0.09 
 Cat  10 (9.3) 2 (3.6) 8 (15.1)  
      
Siblings No siblings  43 (38.7) 22 (39.3) 21 (38.2) 1.0 
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 Siblings  68 (61.3) 34 (60.7) 34 (61.8)  
      
Day Care (up to 36 mo.)*** No day care  46 (42.6) 27 (49.1) 19 (35.8) 0.23 
 Day care  62 (57.4) 28 (50.9) 34 (64.2)  
      
 
*P-values are for Wilcoxon rank sum test for log-transformed total IgE, BMI, gestational age, and early wheeze proportion and 
otherwise for Fisher’s exact test 
 
**Sensitization is based on a serum IgE concentration of 0.35 kU/L to at least one food or environmental allergen, respectively  
 
***Oral steroid use variable was missing for 11 subjects  
Total IgE variable was missing for 10 subjects 
Sensitization (food and environmental) and the breastfeeding variables were missing for 8 subjects  
Maternal 3rd trimester vitamin D concentration was missing for 5 subjects  
Daycare and cat variables were missing for 3 subjects  
Dog variable was missing for 2 subjects  
BMI variable was missing for 1 subject  
 
NA = not applicable  
 
† P-value 0.05 ≤ x ≥ 0.01           
‡ P-value 0.01 ≤ x ≥ 0.001            
‡‡ P-value 0.001 ≤ x ≥0.0001            
‡‡‡ P-value < 0.0001 
 
 
Figure 2.3. Biomass (ng/mL) based on wheeze proportion in the asthma cohort. 
 
Biomass estimates were then used to calculate absolute taxonomic abundance profiles for each 
subject. Unlike with relative abundance (RA) profiling, in which abundances of each taxa can 
only be considered as fractions of overall taxa detected, absolute abundance (AA) profiling 
allows abundance for each taxa to be considered independently. Some subjects had insufficient 
DNA quantity or quality for biomass estimation, so the sample size was reduced to 85 subjects 
and included 45 high wheeze and 40 low wheeze subjects. There was no significant correlation 
between total fecal bacterial biomass and wheeze proportion (Spearman’s 𝜌=-0·15, p=0·18) 
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(Figure 2.3). As expected, at the phylum level, the two most abundant phyla were Bacteroidetes 
and Firmicutes for all subjects (Figure 2.4).   
 
Using RA data, several species-level taxa were positively associated with wheeze (negative 
binomial regression FDR<0·05) including Streptococcus luteciae, Succiniclasticum sp., 
Veillonella dispar, Veillonella parvula, and Lactococcus sp. (Figure 2.5, Table 2-2). After 
adjusting for study site, only the Veillonella species (V. parvula and V. dispar) and S. luteciae 
remained significantly associated with wheeze and an additional unidentified Veillonella sp. was 
also identified as positively associated with wheeze (FDR=2·5×10-2). Bifidobacterium longum 
was the only species negatively correlated with wheeze proportion after adjusting for study site 
(FDR=0·015). Since Bifidobacterium species are known to be associated with breastfeeding, 
this analysis was repeated adjusting for both study site and breastfeeding and it was found that 
B. longum remained independently associated with wheeze proportion (Log2 fold-change=-
2·09; FDR=3·1×10-2).  
 
Using AA data, many of the same species were positively associated with wheeze: 
Succiniclasticum sp., Lactococcus sp., V. dispar, V. parvula, and the same unidentified  
Veillonella sp. (Figure 2.5, Table 2-2). Additionally, Lactobacillus zeae was positively correlated 
with wheeze proportion (FDR=4·04x10-3). Only one species in the Enterobacteriaceae family 
was negatively correlated with wheeze proportion (Log2 fold-change=-2·88; FDR=2·3×10-2). 
After adjusting for study site, only V. dispar (FDR=6·9×10-3) and V. parvula (FDR=3·2×10-2), 
remained positively correlated with wheeze proportion. Enterobactericeae spp. also remained 
negatively correlated with wheeze proportion (FDR=1·2×10-3) (Table 2-2).  Taken together, 
Veillonella species—V. dispar and V. parvula—were consistently identified as positively 
associated with wheeze across all datasets and analyses. 
 
2.2.4 Histidine Metabolism is Positively Associated with Wheeze Proportion 
Of 737 identified fecal metabolites, 20 were positively associated with wheeze proportion 
(Spearman correlation p<0·05). No metabolites were negatively associated with wheeze 
proportion (Table 2-5, https://github.com/dedricks20/asthma_ICS_datafiles). Of the 20 fecal 
metabolites associated with wheeze proportion, 19 had the same direction of association and 
p<0·20 in linear regression analyses adjusted for study site. Most of these 20 metabolites were 
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amino acid metabolites (40%), xenobiotics (20%), or lipids (25%) (Figure 2.6; Table 2-5, 
https://github.com/dedricks20/asthma_ICS_datafiles).  
 
Figure 2.4. Phylum-level microbial composition using relative (A) and absolute abundance (B) data for the 
asthma cohort. As expected, Bacteroidetes and Firmicutes were the dominant phyla for all subjects. Both RA and 
AA data reveal variations in the phyla Verrucomicrobia and Proteobacteria between high and low wheeze subjects. 
 
Metabolites associated with wheeze were enriched in pathway analyses with metabolites of 
histidine metabolism (Pathway Impact Value (PIV)=0·14; p=0·04) (Figure 2.7). Metabolites 
within the histidine pathway associated with wheeze include carnosine, N(pi)-methyl-L-histidine, 
and beta-Alanyl-N(pi)-methyl-L-histidine.  These results were confirmed by over-representation 
analysis (Fisher’s exact test p=0·0001), which also identified dipeptide synthesis as associated 






Figure 2.5. Species are positively and negatively associated with wheeze proportion in the asthma cohort. 
Fold changes in species abundance based on wheeze proportion range from -1.59 to 5.02 and -2.88 to 4.94 for RA 
and AA, respectively. The coral-colored bars represent results from RA data and the dark blue-colored bars represent 
results from AA data. Veillonella dispar and V. parvula were the only species that remained significant across all 
analyses for RA and AA data (crude and adjusted)(negative binomial regression FDR <0.05).  
 
2.2.5 Veillonella Species are Correlated with the Greatest Number of Metabolites  
We created taxon-metabolite Spearman correlation networks. Results reported here are based 
on RA data and results based on AA data can be found in the supplementary material (Table 2-
6, https://github.com/dedricks20/asthma_ICS_datafiles). Amongst wheeze-associated taxa, V. 
dispar and V. parvula were associated (Spearman correlation p<0·05) with the greatest number 
of metabolites (278 and 257, respectively) (Figure 2.8; Table 2-6, 
https://github.com/dedricks20/asthma_ICS_datafiles). Most metabolite correlations with V. 
dispar and V. parvula were positive (235 and 225, respectively). Of 218 metabolites associated 
with both V. dispar and V. parvula, all had the same direction of association: 196 positive and 22 
negatively. Pathway analysis of the 196 metabolites positively correlated with both V. dispar and 
V. parvula revealed no significant pathways. However, over-representation analysis identified 
significant metabolic pathways including lysophospholipid (Fisher’s exact test p=1·9×10-4) and 




Figure 2.6. Fecal metabolites positively associated with wheeze proportion are largely metabolites involved 
in amino acid, xenobiotic, and lipid metabolic pathways for both cohorts. 
Table 2-2. Asthma cohort differential taxa analysis for relative and absolute abundance. Taxa identified as 
over- or under-represented at the species level using negative binomial regression.  
Relative Abundance Data Crude  Adjusted for Study Site 







Streptococcus luteciae 5.02 2.21E-07‡‡‡ 3.16E-05‡‡‡ 4.58 4.20E-06‡‡‡ 6.08E-04‡‡ 
Succiniclasticum sp. 4.73 4.36E-04‡‡ 3.16E-02† 2.04 2.90E-02† 3.24E-01 
Veillonella parvula 3.40 5.61E-06‡‡‡ 2.71E-04‡‡ 3.24 1.18E-04‡‡ 5.72E-03‡ 
Veillonella dispar 3.36 9.13E-06‡‡‡ 3.31E-04‡‡ 3.14 7.87E-05‡‡‡ 5.71E-03‡ 
Lactococcus sp.  3.34 1.10E-04‡‡ 3.19E-03‡ 1.72 5.25E-02 3.69E-01 
Lactobacillus zeae 3.00 2.08E-03‡ 5.03E-02 1.91 5.58E-02 3.69E-01 
Veillonella sp.  2.45 6.58E-03‡ 1.11E-01 3.05 8.61E-04‡‡ 2.50E-02† 
Bifidobacterium longum -1.62 3.42E-03‡ 7.08E-02 -2.06 4.07E-04‡‡ 1.48E-02† 
Enterobacteriaceae spp.  -1.59 3.86E-02 3.11E-01 -2.12 7.30E-03‡ 1.51E-01 
       
Absolute Abundance Data Crude  Adjusted for Study Site 







Succiniclasticum sp. 4.94 3.76E-06‡‡‡ 5.45E-04‡‡ 2.25 3.99E-02† 3.62E-01 
Lactobacillus zeae 4.35 8.25E-05‡‡‡ 4.04E-03‡ 1.94 8.40E-02 5.08E-01 
Veillonella sp. 3.97 1.25E-04‡‡ 4.52E-03‡ 2.07 5.56E-02 4.24E-01 
Lactococcus sp.  3.62 3.19E-04‡‡ 9.26E-03‡ 2.68 9.89E-03‡ 2.01E-01 
Veillonella dispar 3.62 4.10E-05‡‡‡ 2.97E-03‡ 3.49 1.43E-04‡‡ 6.91E-03‡ 
Veillonella parvula  2.92 1.33E-03‡ 2.75E-02† 3.25 8.96E-04‡‡ 3.25E-02† 
Streptococcus luteciae 1.24 2.59E-01 7.66E-01 0.90 4.26E-01 8.91E-01 




Figure 2.7. Histidine metabolism is positively associated with wheeze proportion in the asthma cohort. 
Pathway analyses in Metaboanalyst identified histidine metabolism as enriched in association with wheeze proportion 
based on a calculated pathway impact value (PIV = 0.14; p-value = 0.04; FDR corrected p-value = 1). The specific 




proportion, seven were associated with V. dispar and five were associated with V. parvula 
(Figure 2.8; Table 2-6, https://github.com/dedricks20/asthma_ICS_datafiles). 
 
The only species negatively correlated with wheeze proportion, B. longum, had the greatest 
number of negatively associated metabolites (positively correlated metabolites= 24; negatively 
correlated metabolites= 87) (Figure 2.8; Table 2-6, 
https://github.com/dedricks20/asthma_ICS_datafiles). Metabolites negatively correlated with B. 
longum were enriched in glycerophospholipid metabolites (PIV=0·13; p=0·03). Interestingly, in 
overrepresentation analyses, the same metabolic pathways identified in association with 
Veillonella species, lysophospholipid (negative binomial regression p=2·0×10-3) and dipeptide 
(negative binomial regression p=1·2×10-6) were enriched amongst metabolites negatively 
correlated with B. longum.  
2.2.6 Microbial Correlation Networks Differ Based on Wheeze Frequency 
To identify microbial correlation patterns among high wheeze and low wheeze subjects, a 
network analysis was performed using SparCC. Results reported here are based on AA data 
39 
 
and results, which were largely similar, based on RA data can be found in the supplementary 
material (Table 2-7, https://github.com/dedricks20/asthma_ICS_datafiles). Overall, microbial 
correlation networks were similar in mean degree distribution between high and low wheeze 
proportion subjects, that is, average number of microbes correlated (p<0·05) with each microbe 





Figure 2.8. Veillonella species are correlated with the greatest number of metabolites in the asthma cohort. In 
total, 7 wheeze-associated fecal metabolites were positively correlated with wheeze-associated taxa based on 
relative abundance (RA). Veillonella species, V. dispar and V. parvula, were associated with the largest number of 
metabolites (278 and 257, respectively). Of these, most associations were positive (235 and 225, respectively); 196 
positively and 22 negatively-associated metabolites were shared between these two species. B. longum had the 
largest number of negatively-associated metabolites (n= 87). 
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and low wheeze also had similar numbers of edges (high=93 positive and 22 negative edges; 
low=118 positive and 28 negative edges; Fisher test comparing frequency of positive vs 
negative edges between groups p=1). However, resulting networks displayed minor differences 
in the number of links amongst the wheeze-associated species, V. dispar and V. parvula, with 
more numerous edges in the high wheeze group (V. dispar=6 for high and 4 for low; V. 
parvula=8 for high and 4 for low) (Figure 2.9, Table 2-7, 
https://github.com/dedricks20/asthma_ICS_datafiles). Three positive correlations amongst 
wheeze-associated Veillonella species were conserved between high and low wheeze subjects: 
1) V. dispar and V. parvula (high correlation strength=0·82  and p<0·001; low correlation 
strength=0·74 and p<0·001), 2) V. dispar and Haemophilus parainfluenzae (high correlation 
strength=0·53 and p<0·001; low correlation strength=0·72 and p<0·001), and 3) V. parvula and 
H. parainfluezae (high correlation strength=0·57 and p<0·001; low correlation strength=0·61 
and p<0·001)(Table 2-7, https://github.com/dedricks20/asthma_ICS_datafiles).  
 
2.2.7 ICS Cohort Analysis  
To determine associations of the gut microenvironment and ICS treatment responses in 
children, we analyzed a subgroup of 28 subjects who were treated with ICS between ages three 
and five years (Figure 2.1). Thirteen subjects reported wheeze ≥50% of the time (ICS non-
responders), while 15 subjects reported wheeze <50% of the time (ICS responders). Maternal 
asthma and maternal education were associated with ICS responsiveness (Table 2-3, Maternal 
asthma Fisher’s exact test p=0.007; Maternal education Fisher’s exact test p=0·02) and were 
accordingly included as covariates in models of key results.  
 
There was a non-significant trend of reduced alpha diversity in association with increased 
wheeze proportion (Figure 2.10, Shannon index adjusted linear regression beta=-0·33 (95% CI 
-0·66, 0·003) p=0·052; Simpson index adjusted linear regression beta=-2·72 (95% CI -5·62, 
0·18), p=0·065). In contrast, there were significant differences in Bray-Curtis beta diversity by 
wheeze proportion (Figure 2.7, Adonis PERMANOVA p=0·004).    
 
Several species-level taxa were positively associated with wheeze proportion in the ICS Cohort: 
Veillonella dispar, Roseburia faecis, Succiniclasticum sp., Bacteroides uniformis, and 




Table 2-3  Subject characteristics by ICS response for the ICS cohort. Non-responders are those with reported 
wheeze at least 50% of the time and responders are those with reported wheeze less than 50% of the time between 
ages 3 and 5 years. Mean (standard deviation) is shown for total IgE, body mass index (BMI), gestational age and 
early wheeze proportion; otherwise, numbers (%) are shown for each characteristic. 
 Categories All Children  (n = 28) 
Non-responders 
(n = 13) 
Responders  
(n = 15) p-value 
Sex Female  9 (32.1) 5 (38.5) 4 (26.7) 0.69 
 Male  19 (67.9) 8 (61.5) 11 (73.3)   
      
Race/Ethnicity Black, non-Hispanic  14 (50.0) 7 (53.8) 7 (46.7) 1.00 
 White, non-Hispanic  7 (25.0) 3 (23.1) 4 (26.7)  
 Hispanic or Other  7 (25.0) 3 (23.1) 4 (26.7)   
      
Study Center  Boston  7 (25.0) 2 (15.4) 5 (33.3) 0.68  
 San Diego  2 (7.1) 1 (7.7) 1 (6.7)   
 St. Louis  19 (67.9) 10 (76.9) 9 (60.0)  
      
Vitamin D Treatment  400 IU / day  17 (60.7) 8 (61.5) 9 (60.0) 1.0 
 4,000 IU / day  11 (39.3) 5 (38.5) 6 (40.0)  
      
Maternal 3rd Trimester Vitamin D Levels (ng/mL)*** NA 34.0 +/- 17.0 33.9 +/- 16.7 34.2 +/- 17.9 0.82  
      
Total IgE (kU/L) (log scale)*/*** NA 4.1 +/- 1.7 4.5 +/- 1.9 3.8 +/- 1.5 0.06 
      
Food Sensitization**/*** No sensitization  14 (51.9) 6 (46.2) 8 (57.1) 0.71 
 Sensitization 13 (48.1) 7 (53.8) 6 (42.9)  
      
Environmental Sensitization **/*** No sensitization  16 (59.3)  5 (38.5) 11 (78.6) 0.054 
 Sensitization 11 (40.7) 8 (61.5) 3 (21.4)  
      
Early Wheeze Proportion (0-3 yrs.)* NA 0.55 +/- 0.3 0.73 +/- 0.2 0.40 +/- 0.3 0.006‡ 
      
Body Mass Index (BMI)* NA 17.0 +/- 2.6 17.0 +/- 2.6 17.1 +/- 2.8 1.0 
      
Maternal Asthma  No maternal asthma  15 (53.6) 3 (23.1) 12 (80.0) 0.007‡ 
 Maternal asthma 13 (46.4) 10 (76.9) 3 (20.0)  
      
Maternal Education  Less than college grad  17 (60.7) 11 (84.6) 6 (40.0) 0.02† 
 College grad or higher  11 (39.3) 2 (15.4) 9 (60.0)  
      
Birth Mode  Vaginal birth  18 (64.3) 6 (46.2) 11 (73.3) 0.43 
 C-section birth  10 (35.7) 7 (53.8) 4 (26.7)  
      
Gestational Age (Weeks)* NA 37.2 +/- 3.8 37.3 +/- 3.2 37.2 +/- 4.4 0.78 
      
Breastfeeding*** Formula given before 4 mo.  19 (73.1) 10 (83.3) 9 (64.3) 0.39  
 Strictly breastfed before 4 mo. 7 (26.9) 2 (16.7) 5 (35.7)  
      
Perinatal Antibiotic Exposure  No antibiotic exposure  8 (28.6) 4 (30.8) 4 (26.7) 1.00 
 Antibiotic exposure 20 (71.4) 9 (69.2) 11 (73.3)  
      
Oral Steroid Use Between Age 3 and 5 Years No OCS use   19 (67.9) 6 (42.9) 13 (86.7) 0.04† 
 OCS use 9 (32.1) 7 (57.1) 2 (13.3)  
      
Household Dog  No dog  21 (75.0) 9 (69.2) 12 (80.0) 0.67 
 Dog  7 (25.0) 4 (30.8) 3 (20.0)  
      
Household Cat  No cat  26 (92.9) 12 (92.3) 14 (93.7) 1.00 
 Cat  2 (7.7) 1 (7.7) 1 (6.7)  
      
Siblings No siblings  13 (46.4) 4 (30.8) 9 (60.0) 0.15 
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 Siblings  15 (53.6) 9 (69.2) 6 (40.0)  
      
Day Care (up to 36 mo.) No day care  16 (57.1) 7 (53.8) 9 (60.0) 1.00 
 Day care  12 (42.9) 6 (46.2) 6 (40.0)  
      
 
*P-values are for Wilcoxon rank sum test for log-transformed total IgE, BMI, gestational age, and early wheeze proportion and otherwise for 
Fisher’s exact test 
 
**Sensitization is based on a serum IgE concentration of 0.35 kU/L to at least one food or environmental allergen, respectively  
 
*** Maternal 3rd trimester vitamin D concentration and breastfeeding variables were missing for 2 subjects  
IgE and sensitization (food and environmental) variables were missing for 1 subject  
 
NA = not applicable 
       
 
† P-value 0.05 ≤ x ≥ 0.01           
‡ P-value 0.01 ≤ x ≥ 0.001            
‡‡ P-value 0.001 ≤ x ≥0.0001           




Figure 2.9. Species co-occurrences based on wheeze frequency in asthma and ICS cohorts. Species 
abundance correlations were analyzed using absolute abundance data based on wheeze frequency (high, low) and 
ICS (non-responders, responders). All correlations with a SparCC correlation coefficient ≥0.45 for the asthma cohort 
and ≥0.60 for the ICS cohort were included in the network. Node size corresponds to mean centered log-ratio 
transformed abundance for each taxa (a and c). Although networks did not reveal obvious differences in network 
structure (i.e., correlation type(s), correlation direction, mean degree distribution), distinct differences were observed 
in species correlations amongst wheeze-associated species in both asthma and ICS cohorts. In the asthma cohort, V. 
dispar (Vd) and V. parvula (Vp) had the largest number of positive microbe-microbe correlations in subjects with high 
wheeze proportion compared to their low wheeze counterparts (b). In the ICS cohort, non-responders had more 




Figure 2.10. Differences in diversity are observed based on ICS responsiveness. No significant differences in 
alpha diversity were observed at the species level based on wheeze proportion (Shannon index Pearson rho = -0.22, 
p -value= 0.25; Simpson index Pearson rho = -0.28, p-value=0.15), however, there was a trend toward reduced alpha 
diversity in association with increased wheeze proportion (A). A PCoA with Bray-Curtis dissimilarity shows that 
subjects form distinct groups based on their ICS responsiveness. Non-responders are represented by purple circles. 





Figure 2.11. Species are positively and negatively associated with wheeze proportion in the ICS cohort. Fold 
changes in species abundance based on wheeze proportion range from -5.36 to 6.74 and -5.34 to 7.69 for RA and 
AA, respectively. The turquoise-colored bars represent results from RA data and the coral-colored bars represent 
results from AA data.  The highest fold change in abundance in association with wheeze was observed for the 
species Veillonella dispar. All species were significant after FDR correction (negative binomial regression FDR <0.05) 
for RA and AA data, except for H. parainfluenzae and Phascolarctobacterium sp. No species were significantly 
associated with wheeze after adjusting for maternal asthma, education and FDR correction (negative binomial 
regression FDR <0.05) in both datasets. 
Table 2-4. ICS cohort differential taxonomic analysis for relative and absolute abundance data. Taxa identified 
as over- or under-represented at the species level using negative binomial regression.   
Relative Abundance Data Crude  Adjusted for Maternal Education and Maternal Asthma 




Log2 Fold  
Change 
p-value FDR-corrected  
p-value 
Veillonella dispar 6.74 5.32E-07‡‡‡ 7.61E-05‡‡‡ 1.56 2.76E-01 7.60E-01 
Succiniclasticum sp. 4.98 8.14E-04‡‡ 2.33E-02† 4.09 3.60E-03‡ 1.71E-01 
Roseburia faecis 4.58 1.46E-04‡‡ 1.05E-02† 2.09 1.14E-01 7.10E-01 
Bacteroides uniformis 4.27 3.40E-04‡‡ 1.40E-02† 3.60 7.52E-03‡ 2.69E-01 
Haemophilus parainfluenzae 4.04 3.09E-03‡ 6.69E-02 3.43 1.77E-02† 4.21E-01 
Phascolarctobacterium sp. -1.95 1.90E-01 6.64E-01 -2.47 9.66E-02 7.10E-01 
EtOH8 spp. -5.36 3.92E-04‡‡ 1.40E-02† -3.25 1.92E-02† 4.21E-01 
       
Absolute Abundance Data Crude  Adjusted for Maternal Education and Maternal Asthma 








Veillonella dispar 7.69 1.35E-06‡‡‡ 1.93E-04‡‡ 2.77 8.96E-02 7.64E-01 
Roseburia faecis 5.98 6.74E-06‡‡‡ 4.82E-04‡‡ 3.73 1.13E-02† 4.04E-01 
Succiniclasticum sp. 5.44 1.46E-03‡ 4.16E-02† 4.52 3.64E-03‡ 1.80E-01 
Bacteroides uniformis 4.68 6.16E-04‡‡ 2.94E-02† 2.95 5.20E-02 6.80E-01 
Haemophilus parainfluenzae 4.00 1.21E-02† 2.48E-01 3.68 2.41E-02† 4.98E-01 
EtOH8 spp. -0.47 7.63E-01 9.90E-01 -0.45 7.32E-01 9.85E-01 




significantly associated with wheeze after FDR correction. However, previous research (239) 
and our data (discussed below) support this species’ purported correlation with ICS response. 
 
Of the 737 fecal metabolites, 126 were positively associated with wheeze proportion (Spearman 
correlation p<0·05) and six were negatively associated with wheeze proportion (Spearman 
correlation p<0·05) in the ICS cohort (Table 2-5, 
https://github.com/dedricks20/asthma_ICS_datafiles).  Of the 132 fecal metabolites associated 
with wheeze proportion, 119 (90·2%) had the same direction of association with  
wheeze proportion and p<0·20 in linear regression analyses adjusted for maternal education 
and maternal asthma.  
 
The number of metabolites associated with wheeze was higher in the ICS cohort (132 
metabolites) than in the asthma cohort (20 metabolites). The 20 metabolites positively 
associated with wheeze proportion in the asthma cohort were also positively associated with 
wheeze proportion in the ICS cohort. Of these, 11 associations reached statistical significance 
(p < 0.05) (Figure 2.6).  
 
Sphingolipid metabolism was the only pathway enriched in children with higher wheeze 
proportion (Pathway Impact Value (PIV)=0·47; p=0·046). Metabolites within the sphingolipid 
pathway associated with wheeze included L-serine, sphinganine, sphingosine, N-
acylsphingosine (a ceramide), and phytosphingosine. The enrichment of the sphingolipid 
pathway was confirmed using over-representation analysis (Figure 2.12; Fisher’s exact test 
p=0·004).  
 
In a Spearman microbe-metabolite correlation network analysis using RA data, 52 wheeze-
associated metabolites were positively correlated with wheeze-associated taxa. Of these, 
H. parainfluenzae and V. dispar were correlated with the greatest number of wheeze-associated 
metabolites (32 and 22, respectively) (Figure 2.13; Table 2-8, 
https://github.com/dedricks20/asthma_ICS_datafiles). Microbial correlation networks, where 
edges were based on permutations-based p<0·05 and correlation strength ≥0·60 or ≤-0·60, 
were similar in mean degree (non-responders=3·3 +/- 3·8; responders=3·7 +/- 3·8; Wilcoxon 
test p=0·26) and had a similar number of overall positive and negative edges (non-responders: 
positive=131, negative=102; responders: positive=154, negative=111; Fisher test p=0·72). 
Despite requiring a stronger correlation strength in the ICS cohort microbial network (0·60) 
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compared to the asthma cohort network (0·45), significant correlations were more numerous in 





Figure 2.12. Sphingolipid metabolism is positively associated with wheeze proportion in the ICS cohort. 
Pathway analyses in Metaboanalyst identified sphingolipid metabolism as enriched in association with wheeze 
proportion based on a calculated pathway impact value (PIV). The specific metabolites identified as significant 
include L-serine, sphingosine, sphinganine, N-acylsphingosine (i.e., ceramide), and phytosphingosine. 
 
In microbial network analyses, we observed striking differences in the number of links amongst 
wheeze-associated species between ICS responders and non-responders. Wheeze-associated 
taxa had more numerous significant (p<0·05) microbial correlations among non-responders 
(pos=20; neg=20) compared to responders (pos=11; neg=6) (Figure 2.8; Table 2-9, 
https://github.com/dedricks20/asthma_ICS_datafiles). The wheeze-associated species with the 
largest number of links to other microbes were V. dispar (non-responders=12; responders=3) 
and H. parainfluenzae (non-responders=12 responders=3) (Table 2.9). H. parainfluenzae and V. 
dispar were correlated with one another in both responders (correlation strength=0·63; p<0·001) 
and non-responders (correlation strength=0·67; p<0·001, Table 2.9). Only four of the significant 
microbial correlations with wheeze-associated species in the non-responder network were 
conserved in the responders’ network. Overall, we found similar network structure but more 
numerous correlations among wheeze-associated species in ICS non-responders compared to 






Figure 2.13. Haemophilus parainfluenzae and Veillonella dispar are correlated with the greatest number of 
metabolites in the ICS cohort. In total, 52 wheeze-associated fecal metabolites were positively correlated with 
wheeze-associated taxa based on relative abundance (RA) data. Overrepresentation analyses did not reveal any 
metabolic pathways enriched in the wheeze-associated subset. H. parainfluenzae and V. dispar were associated with 







2.3 Discussion  
Previous work has pointed to an association between airway microbiota and asthma and allergic 
diseases.(289,297,298) Airway microbiota have also been shown to vary in adults based on 
corticosteroid responsiveness.(239) While the airway microbiome inevitably affects asthma 
outcomes, several studies have also shown that gut microbiota can affect inflammatory 
responses at distal sites, including the lung, and influence the incidence and/or progression of 
both acute and chronic diseases of the airway.(208,220,299–306) As demonstrated, gut 
microbiota have an established role in asthma development, however, less is known about its 
contribution to morbidity in children with asthma; particularly its role in existing asthma. The aim 
of this study was to determine if wheeze frequency and/or ICS responsiveness are correlated 
with differences in gut microbiome and metabolome in children with asthma.  
2.3.1 Wheeze-associated Taxa 
Of the taxa positively associated with wheeze, Veillonella species and H. parainfluenzae were of 
particular interest due to their suggested role in asthma and corticosteroid resistance.(239,307)  
Veillonella species, particularly V. dispar, were strongly correlated with wheeze proportion in 
both asthma and ICS cohorts. Veillonella spp. are commensal bacteria of the mouth and 
gastrointestinal tract, however, overgrowth of Veillonella species in the airway has been 
implicated in decreased lung function and asthma exacerbations.(307) Yet, other studies have 
found Veillonella species to be enriched in non-asthmatic adults (236) and decreased in the 
lungs of corticosteroid-resistant adults.(239) The role of Veillonella species in asthma may also 
extend to the gut microbiome. Veillonella abundance in the infant gut has been associated with 
the risk of subsequent asthma development, though the directions of associations have not 
been consistent between studies. (230) Current discrepancies in the role of Veillonella in 
asthma development and morbidity warrant further research into the mechanisms underlying 
this species’ effect on lung function and asthma pathology. This disparity may reflect a 
difference in study methodology, or it could reflect a diversity of functional capacities among 
species and strains of the genus Veillonella as well as differences in the impact of Veillonella 
presence at different body sites.   
 
Haemophilus parainfluenzae was positively associated with wheeze proportion in the ICS 
cohort. Although this association was not significant after FDR correction, metabolite and 
species correlation analyses speak to its relevance in childhood asthma. Several studies in 
adults have observed an increased abundance of Haemophilus species in the airway of 
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asthmatics (233–235,237,238). H. parainfluenzae has also been associated with corticosteroid 
resistance.(239) This gram-positive Proteobacteria is another commensal species of the 
gastrointestinal and upper respiratory tract and is thought to: 1) directly inhibit mitogen-activated 
protein kinase 1 (MKP-1) induction; a pathway activated by corticosteroids to suppress the 
inflammatory response and 2) initiate asthma inflammation by activating transforming growth 
factor β-activated kinase 1 (TAK1) and p38 mitogen-activated protein kinase (MAPK) pro-
inflammatory pathways along with downstream interleukin-8 (IL-8) production.(239) These data  
implicate H. parainfluenzae in the pro-inflammatory response in asthma while also reducing the 
efficacy of corticosteroids through direct inhibition of anti-inflammatory pathways.  
2.3.2 Wheeze-associated Metabolites and Metabolite-microbe Correlations 
Histidine metabolites were positively associated with wheeze in the asthma cohort. Histidine is a 
precursor to histamine and an important immunomodulator affecting both the innate and 
adaptive immune response.(308) Increased fecal expression of histidine decarboxylase has 
been observed compared in adults with asthma and is known to contribute to bronchospasms, 
mucus secretion, edema, and inflammation in asthmatics.(244,281,308) Although mast cells 
and basophils are the principal producers of histamine, many gut microbiota also produce 
histamine.(281,309) Our findings suggest that variations in histamine metabolism in the gut are 
associated with morbidity in individuals with existing asthma. 
 
In the ICS cohort, sphingolipid metabolites were positively associated with wheeze. Sphingolipid 
metabolites, such as ceramide and sphingosine-1-phosphate (S1P), are signaling molecules 
that regulate a range of pro-inflammatory processes and are thought to influence asthma-
associated inflammation and pathophysiology. (310) However, the interplay between 
sphingolipids, the immune system and asthma is not yet fully understood. Previous research 
has shown that decreases in de novo biosynthesis of sphingolipids enhances airway 
responsiveness independent of allergy or inflammation. (250,310,311) Yet, increased levels of 
ceramide and S1P have been observed in the lungs of asthmatics along with increases in 
airway hyperresponsiveness in both animal and human studies. (262,310,312–314)  
 
Very few studies have directly compared the metabolic profiles of responders and non-
responders, however, one recent study found that adults with uncontrolled asthma had distinct 
cellular markers and metabolic profiles compared to adults with controlled asthma including 
higher concentrations of sphingosine and several ceramide species (C16:0 and C24:0) in blood 
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serum. (251) These data suggest that sphingolipid metabolites are associated with an 
uncontrolled/non-responsive asthma subtype.  
 
Interestingly, a greater number of metabolites were associated with wheeze in the ICS cohort 
despite its significantly smaller sample size (Table 2.3). We also find a more robust association 
between microbial composition and wheeze in the ICS cohort. These data suggest that the 
microenvironment of the gut associates more strongly with treatment response than overall 
asthma control in childhood asthma.   
2.3.3 Microbial Networks  
Network analyses revealed differences in microbial correlations based on wheeze frequency 
and ICS responsiveness, however, many network attributes were similar between cohorts: 1) 
both showed similar mean degree distribution between groups (high wheeze vs. low wheeze; 
non-responder vs. responder) and similar direction distributions (i.e., positive vs. negative); 2) 
amongst wheeze-associated species, most links were positive; and 3) the positive correlation 
between H. parainfluenzae and V. dispar was conserved across all cohorts/groups. In contrast, 
the ICS cohort displayed a number of distinct features compared to the asthma cohort: 1) 
species’ correlations amongst wheeze-associated species were not as well conserved between 
responders and non-responders; 2) overall correlation strengths were stronger; and 3) overall 
network connectivity was higher.  
 
In the ICS cohort, the lack of correlations amongst wheeze-associated taxa in responders was 
of particular interest. These data suggest that ICS response may not be determined simply by 
the presence/absence of species and that underlying associations/networks of species (or 
perhaps metabolites) should also be considered.  
 
Overall, our study provides evidence that the gut microbiome and metabolome have an impact 
on wheeze frequency and ICS responsiveness in childhood asthma. The strength 
of this study lies in its use of absolute abundance data - which is often lacking in microbiome 
association studies - and longitudinal dense phenotyping of a diverse sample. Although 
associations and significance levels in the ICS cohort were often weak or non-significant after 
correcting for multiple testing and/or covariates, much of this can be attributed to our small 
cohort. Thus, further research with larger study cohorts that includes a more robust absolute 
abundance dataset, is required to corroborate these findings.     
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2.4 Materials and Methods  
2.4.1 VDAART Study Design 
VDAART is a double-blind placebo-controlled study on the effects of prenatal vitamin D 
supplementation on asthma in offspring. Pregnant women were recruited during the first 
trimester of pregnancy from three sites across the United States: Boston University, 
Massachusetts; Washington University at St. Louis, Missouri; and Kaiser Permanente Southern 
California Region, San Diego, California. All women (n = 876) had a history of asthma, eczema, 
or allergic rhinitis, and/or had a partner (biological father of the infant) with a history of asthma, 
eczema, or allergic rhinitis. After delivery, 806 children were followed using an over-the-phone 
quarterly health questionnaire and annual in-person visits. Stool samples were collected from 
children at age three years for microbiome and metabolome analysis (n = 506).  
2.4.2 Selection of Sample 
Asthma Cohort: Subjects were selected from VDAART participants based on the following 
criteria: i) parent-reported doctor-diagnosed asthma, ii) the majority (>50%) of quarterly health 
questionnaires were completed between the ages of three and five years, and iii) microbiome 
sequencing data available from stool samples collected at age three years. We refer to this 
group as the Asthma Cohort (n = 111).  
 
ICS Cohort: A subgroup (n = 28) of the Asthma Cohort whose parents/guardians reported use 
of ICS on at least 50% of the completed questionnaires between ages three and five years.  
2.4.3 Clinical Outcome 
Asthma Cohort: We calculated the proportion of available quarterly questionnaires between 
ages three and five years in which parents reported wheeze since the last questionnaire. We 
refer to this continuous variable as wheeze proportion. We defined wheeze frequency as a 
dichotomous variable to categorize subjects as either high wheeze (i.e., reported wheeze on 
≥33% of the completed questionnaires (n = 56)) or low wheeze (i.e., reported wheeze <33% of 
the time (n = 55)). The cut-off of 33% was selected to ensure approximately equal subject 
numbers in each group. 
ICS Cohort: A dichotomous variable, ICS response, categorized subjects as either non- 
responders (i.e., reported wheeze on ≥50% of the completed questionnaires (n = 13)) or 
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responders (i.e., reported wheeze <50% of the time (n = 15)). The cut-off of 50% was selected 
to ensure approximately equal subject numbers in each group. 
2.4.4 Fecal Microbiome and Metabolome Profiling 
2.4.4.1 Microbiome Profiling 
Microbiome profiling was performed on stool samples collected at age three years by 
sequencing the 16S rRNA hypervariable region 4 (V4) on the Illumina MiSeq platform, as 
previously described.(315) Samples with <1000 reads were excluded. Closed-reference OTU 
picking was performed with QIIME and genes were annotated using Greengenes.(316,317) 
OTUs present in <5% of samples were excluded.  
2.4.4.2 Quantitative Microbiome Profiling  
Quantitative PCR was also performed with universal 16S rRNA primers to estimate the total 
bacterial biomass for each sample using a previously published method.(315) Relative 
abundance data is widely used to study microbiome and metabolome composition in relation to 
both health and disease states (222,296,318–320); however, these data are subject to 
compositionality effects.(296) Absolute abundance data can provide an increased detection of 
microbiome/metabolome compositional variation between/within individuals over time; a higher 
sensitivity for co-variation in species networks; and decreased false discovery rates.(296,321–
323) Thus, in this study, we consider both relative abundance (RA) and absolute abundance 
(AA) data in the appropriate analyses.   
 
Briefly, a standard curve was generated using serial dilutions of E. coli genomic DNA 
(Affymetrix/USB, ATCC 11303 strain, Santa Clara, CA). Samples with less than 15 ng of DNA 
per mL of stool or a PCR threshold less than eight or greater than 36 were excluded from the 
analysis. For this study, absolute taxonomic abundances were estimated at the species level by 
multiplying the estimated bacterial biomass (ng/µL) by the relative abundance. This was then 
multiplied by a constant (10,000) and rounded to the nearest integer. Of the 111 asthma cohort 
subjects, 85 were included in the quantitative abundance analysis. Excluded subjects (n = 26) 
did not pass the quality thresholds described above. Of the 28 ICS cohort subjects, 22 were 
included in the quantitative abundance analysis.  
2.4.4.3 Metabolomic Profiling  
Untargeted metabolomic profiling was performed using UPLC-MS/MS by Metabolon, Inc., as 
previously described.(315,324)  
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2.4.5 Statistical Analyses  
2.4.5.1 Baseline Characteristics  
T-tests and Fisher’s exact tests were performed to study associations between wheeze 
frequency or ICS responsiveness with baseline subject characteristics. 
2.4.5.2 Alpha and Beta Diversity  
Species-level alpha diversity Shannon and Simpson indices were calculated using the vegan R 
package. Pearson correlations and linear regression were used to seek associations between 
alpha diversity and wheeze frequency or ICS responsiveness. For beta diversity, reads were 
scaled to an even depth (based on minimum read count) and the species-level Bray-Curtis 
dissimilarity matrix was calculated using the Phyloseq R package. PERMANOVA (Adonis) was 
used to test for differences in Bray-Curtis beta diversity by wheeze frequency/ICS 
responsiveness.   
2.4.5.3 Differential Taxa Analysis  
Differential taxa analysis was conducted using negative binomial regression models to identify 
taxa associated with wheeze proportion using the R phyloseq-DEseq2 package. The R package 
phyloseq is a dedicated object-oriented data analysis tool for phylogenetic sequencing 
data(325) and has been widely used in microbiome research related to human health(326–328) 
and the environment.(121,329) DEseq2 was originally designed to improve the stability and 
reproducibility of RNAseq results, however, it can be broadly applied to other types of high-
throughput count data, such as metagenomics data.(330)  
2.4.5.4 Metabolomic Analysis   
Analyses were conducted on 737 stool metabolites with known identities. Spearman correlation 
tests identified metabolites associated with wheeze proportion. Pathway analyses were 
performed on metabolites with Human Metabolome Database (HMDB) annotations using 
Metaboanalyst v4·0 (www.metaboanalyst.ca). Pathway significance, reported as Pathway 
Impact Value (PIV), is measured based on how many metabolites within the pathway are 
significantly associated with the outcome as well as how important significant metabolites are in 
terms of connectivity to other metabolites within the pathway.  Over-representation analyses 
using Fisher’s exact test were also performed as several metabolites did not have HMDB 
identifiers and could not be included in the Metaboanalyst subpathway analysis. For over-
representation analyses, metabolite pathway annotations were supplied by Metabolon in which 
a single pathway annotation is assigned to every metabolite.    
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2.4.5.5 Network Analyses 
We used Spearman correlation analysis to identify associations between metabolites and 
species. Microbial correlation networks were constructed for at the species level via SparCC 
(Sparse InversE Covariance estimation for Ecological Association and Statistical Inference) 
using the SpiecEasi R package.(331) To determine the significance of correlations (i.e., links), 
we compared our model to a null model using 100 bootstrap iterations as previously 
described.(57) A robust correlation was included in the network if the value of the SparCC 
correlation coefficient was ≥0·45 for positive correlations, ≤-0·45 for negative correlations and 







































Chapter 3                                                               
When Does a Lotka-Volterra-like Model 
Represent Microbial Interactions? Insights from 
in vitro Nasal Bacterial Communities   
 
The content of this Chapter is adapted from the following manuscript:  
Dedrick, S and Momeni B, et al. When does a Lotka-Volterra-like Model Represent Microbial 
Interactions? Insights from in vitro Nasal Bacterial Communities. Manuscript Completed. 
 
Author contributions:  
Sandra Dedrick (SD) and Babak Momeni (BM) conceived and designed the study. BM 
supervised the study. SD performed all experiments and all subsequent analyses. BM 
developed the computational model. SD and BM tested the computational model. SD wrote the 
manuscript. BM edited the manuscript.  
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3.1 Introduction  
Major perturbations to the human microbiome can significantly alter microbial community 
composition and stability which can then result in long-term dysbiosis and disease (332). 
Recently, the medical field has turned towards microbiota-associated therapies (e.g., microbiota 
transplants) as a viable treatment option for diseases associated with dysbiosis. Early 
applications of such therapies have shown great promise; however, a large knowledge gap 
exists regarding what strategies will work best to manipulate the complex, dynamic ecosystem 
of human microbiota. A comprehensive understanding of interspecific and abiotic interactions is 
required to understand how diversity is maintained in health, how perturbations lead to dysbiosis 
in disease, and how best to alter the community composition for therapeutic purposes.  
 
Different approaches have been utilized to investigate the structure and function of microbial 
communities including human cross-sectional and longitudinal studies (74,333–337)), in vitro 
(338–340), and in vivo investigations (341–344). While each approach provides its own level of 
resolution and insight, each also has its own unique set of limitations. Human studies can offer a 
broad overview of host-microbe associations but are primarily descriptive in nature. Conversely, 
in vitro experiments can provide evidence into the specific mechanisms at play but are limited in 
their ability to emulate in vivo conditions. Both datasets provide useful insight into microbial 
community dynamics and, to converge these distinct phenomenological and mechanistic 
inquiries, a mathematical model has proven to be a powerful tool.  
 
Previous studies have considered the use of simplified models, including Lotka-Volterra (LV) 
type models, to represent microbial communities. In some cases, this approach has been 
successful in making predictions about interspecies interactions (345), predicting species 
coexistence (346), and even community structure and dynamics (338,339). At the same time, 
there are concerns about the applicability of such simplified models for representing the 
community; simpler models may inadequately capture resource- or signal-mediated interactions 
(347,348), or omit higher-order interactions (347,349). The question of when LV modeling is a 
good approximation for a community remains open.   
 
In this study, we use an in vitro nasal microbiota consortia to determine when a LV-like model is 
appropriate for describing microbial community dynamics. For this, we tested isolates in 
conditions with potential relevance to nasal microbiota along with cell-free spent media (CFSM) 
conditions to quantify species’ interactions. Species growth parameters derived from in vitro 
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experiments were then used to inform a LV-like model. To assess whether our LV-like model 
accurately represents nasal microbiota, we conducted coculture experiments and compared 
experimental results to the model-derived outcomes.   
 
Our in vitro data reveals general trends of growth across both species and conditions. 
Specifically, species’ growth rates and growth yields (i.e., carrying capacities) were positively 
and linearly correlated when grown in low nutrient concentrations (10% - 0.32% media) and in 
the presence of other species’ CFSMs (i.e., supernatants). Thus, only one parameter for growth 
was required to capture species’ growth dynamics, thereby simplifying the model. We show that 
such a linear correlation between growth rate and yield is consistent with a LV model. 
Furthermore, when we compared our coculture experimental data with our modeling outcomes 
under low nutrient conditions, we found that our LV-like model offered an adequate 
approximation of two-species experimental outcomes throughout exponential growth. 
 
To alter microbial community composition for therapeutic purposes, an accurate and reliable 
modeling framework capable of predicting microbial community outcomes is required. Lotka-
Volterra equations have been utilized to describe a breadth of microbial communities, yet, little 
is known about the conditions in which this modeling framework is successful. Here, we show 
that a set of simple in vitro experiments can reveal whether a LV model is appropriate for 
describing microbial interactions of interest. We speculate that if growth rate-yield trends remain 
consistent in the presence of other species’ supernatant, then a LV is a good candidate for 
predicting microbial community outcomes. However, further assessment is needed to identify 
potential limitations and to determine how generalizable these principles are to other microbial 
communities.  
 
3.2 Results  
3.2.1 Nasal Microbiota as a Model for Microbiota-based Therapies 
The nasal cavity is a reservoir to diverse phyla and has been established as a first-line defense 
against pathogenic invasion and subsequent respiratory infection (8,74,93). It is also home to 
several pathobionts, such as Staphylococcus aureus, which can result in life-threatening 
systemic infection (350). Previous work has demonstrated that nasal microbiota can be altered 
using microbiota-based therapy (351,352). In one such study, the direct nasal administration of 
a nasal commensal species resulted in the eradication of S. aureus, making this microbiome a 
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likely candidate for future microbiota-based therapeutics (352). Former research has also 
demonstrated the importance of interspecies interactions in shaping the composition of this 
community, and a number of commensal-produced compounds that inhibit the colonization of 
pathogens, such as Staphylococcus aureus, have been identified (1,106,107,353). These 
attributes enable us to study interactions in vitro and provide a useful platform for developing a 
mathematical model. We also chose to use nasal microbiota as our model consortia since 1) it 
is relatively low in diversity, harboring only 3-8 species (60), 2) common nasal colonizers are 
culturable and able to be studied using in vitro laboratory experiments, and 3) the nasal cavity 
can be easily sampled. For details regarding nasal strains used in this study and the 
experimental setup, refer to the Methods section and Figure 3.1.   
 
3.2.2 Growth Rate and Yield are Positively Correlated in Spent Media of Other 
Species 
Cell-free spent media (CFSM) experiments are commonly used to investigate bacterial 
interactions with other bacteria, viruses, and eukaryotes (338,354–359). The factors assayed in 
these experiments can include resource consumption, the secretion of metabolic byproducts, 
the production and secretion of additional nutrients, and/or the production of growth inhibitors 
(e.g., antibiotics, small molecules). To quantify the total growth effect of individual species on 
one another, we exposed each species to the CFSM derived from species’ monocultures (see 
Methods). A linear regression model revealed a positive relationship between the growth rate 
and growth yield of each species grown in the CFSMs of our group of nasal bacteria, including 
its own (p-value < 0.05). This suggests that CFSM modulates growth rate and the yield of nasal 
microbiota in a similar manner (Figure 3.2).  
 
3.2.3 Correlated Growth Rate and Yield Is Consistent with Lotka-Volterra 
Modeling of Species Interactions 
We can show that the positive, linear correlation observed in our data is consistent with a Lotka-
Volterra representation of interactions between bacteria (see Supplementary Material). 
Assuming a Lotka-Volterra model, the growth rate (𝑟𝑖𝑗) and carrying capacity (𝐾𝑖𝑗) of species i in 










Figure 3.1 Experimental setup for growth assays. Experimental setup for growth assays in varying environmental 
conditions. Species were grown for 16-18 hours in 12 mLs of 10% THY (pH 7.2) and then transferred into different 
environmental conditions varying in concentration. These conditions include various: nutrients concentrations, 
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metabolic byproduct concentrations, antibiotic concentrations, and environmental pH. For each species-condition 
combination, a linear regression was performed on growth rate and carrying capacity data to determine the 
relationship between these two growth characteristics. Experimental setup for cell-free spent media conditions 
(CFSM). Species were grown for 16-18 hours in 12 mLs of 10% THY (pH 7.2) and cell-free supernatants were filter-
sterilized. Monocultures of each species were also grown under the same conditions. All species were then grown in 
the presence of all other CFSM monocultures. To simulate coculture outcomes (of species i and species j), data 
derived from CFSM experiments were used to inform a generalized LV (gLV) computational model. Correlation 
coefficients were calculated using the carrying capacity from each species grown in standard media (baseline growth 
characteristics), along with the carrying capacity of each species grown in the presence of one another’s CFSM. 
Growth rates from the standard media condition were also included in the model. Simulated outcomes were then 
compared to the experimental outcomes from coculture experiments. 
which depends on the growth rate and carrying capacity of the species being tested (𝑟𝑖 and 𝐾𝑖), 
and not the properties of the species used for the spent media. Thus, we hypothesize that the 
growth rate-yield relationship derived from CFSM experiments can be used to indicate whether 
a Lotka-Volterra-like model is a suitable framework for describing pairwise species interactions.  
Figure 3.2. Growth rate-yield results from nasal species grown in the presence of other nasal species’ cell-





3.2.4 Growth Rate-Yield Correlations Are Consistently Observed in Complex, Low 
Nutrient Environments 
In our data, we observe a positive association between growth rate and yield in CFSM 
experiments. In fact, for ~50% of CFSM conditions, species grow to <30% of their growth yield 
potential and ~80% of the low growth yield interactions also have a low growth rate. One 
explanation is that CFSM is depleted of nutrients required for growth. To test this, we grew each 
species in a range of nutrient concentrations to determine if growth rate and yield are similarly 
modulated by environmental concentrations of growth-limiting nutrients (i.e., carbon, nitrogen, 
phosphorus). As described in the Methods section, species were grown in decreasing 
concentrations (100% - 0.032%) of two different rich medias, THY+T80 and BHI+T80. Both 
medias contain a range of nutrients required for bacterial growth at high concentrations, making 
them both complex and rich in nature. In these experiments, we observe a positive correlation 
between growth rate and yield at low nutrient concentrations (≤5%) (Figure 3.3 and 3.4). 
However, at higher nutrient concentrations (≥10%), the relationship between growth rate and 
yield deviates from the positive correlation (Figures 3.5 and 3.6). Some species, in fact, show a 
local negative correlation between growth rate and yield at higher nutrient concentrations, 
including S. aureus. These data suggest that the positive relationship between growth rate and 
yield only applies to environments with lower concentrations of nutrients. Most 
microenvironments that support microbial communities are nutritionally complex yet low in 
concentration (360). Similarly, previous studies on the nasal environment have shown that the 
nasal cavity contains a range of nutrients at low concentrations (38). Thus, an interaction-based 
model that includes simple growth parameters remains applicable to biologically relevant 
environments, such as the nasal microbiome.  
 
Previous work in Eschericia coli has shown that nutrients, such as carbon and nitrogen, lower 
bacterial growth yield but not growth rate when grown in limiting concentrations (361). To 
determine if single nutrient sources similarly affect growth yield (but not rate) for nasal 
microbiota, we performed similar experiments in a well-defined media, Baseline Defined Media 
with Amino Acids (BAAD). Here, we grew each species in a range of media dilutions between 
100% and 1.25%. When we compare carbon concentrations to each species’ growth rate and 
growth yield separately, we observe a strong linear and positive correlation between carbon 
concentrations and growth yield, but not growth rate (Figures 3.7 and 3.8). These data suggest 
that growth yield is largely affected by nutrient concentrations and growth rate may be limited by 




Figure 3.3. Growth rate-yield results from nasal species grown in low concentrations (5% - 0.32%) of Todd 
Hewitt Broth with Tween 80 (THY+T80). A linear regression analysis reveals a strong positive relationship between 
growth rate and yield when species are grown in low nutrient concentrations.   
 
Figure 3.4. Growth rate-yield results from nasal species grown in low concentrations (10% - 0.63%) of Brain 
Heart Infusion with Tween80 (BHI + T80). A linear regression analysis reveals a strong positive relationship 
between growth rate and yield when species are grown in low nutrient concentrations.   
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Figure 3.5. Growth rate-yield results from nasal species grown in high concentrations (100% - 10%) of Todd 
Hewitt Broth with Tween80 (THY+T80). A linear regression analysis shows no strong relationship between growth 
rate and yield when species are grown in high nutrient concentrations.   
 
Figure 3.6. Growth rate-yield results from nasal species grown in high concentrations (100% - 10%) of Brain 
Heart Infusion with Tween80 (BHI + T80). A linear regression analysis shows no strong relationship between 




Figure 3.7. Growth rate of nasal species grown in various carbon concentrations (0.1 M , 0.075 M, 0.05 M, 
0.025 M, 0.0175 M, 0.015 M, 0.0125 M, 0.0 M). A linear regression analysis shows a weak correlation between 
growth rate and carbon concentrations. 
 
 
Figure 3.8. Growth yield of nasal species grown in various carbon concentrations (0.1 M , 0.075 M, 0.05 M, 
0.025 M, 0.0175 M, 0.015 M, 0.0125 M, 0.0 M). A linear regression analysis shows a positivie correlation between 
growth yield and carbon concentrations. 
65 
 
3.2.5 Growth Rate-Yield Relation can Deviate from a Positive Linear Trend in the 
Presence of Individual Growth Mediators  
Bacteria can influence other bacteria by changing their local microenvironment. This can take 
place through a variety of compounds. We picked three representative examples to explore how 
modulation of the microenvironment might affect species interactions. We examined interactions 
through the production of metabolic intermediates, antibiotic compounds, and alteration of the 
environmental pH. To determine if the relationship between growth rate and yield is conserved 
in the presence of such factors commonly found in the bacterial microenvironment, we 
performed monoculture experiments in increasing concentrations of two common bacterial 
metabolic byproducts acetic acid and lactic acid; in increasing concentrations of two antibiotics 
which represent two distinct classes of antimicrobials; and in the presence of a range of pH 
values. 
In these conditions, we observe a non-predictable relationship between growth rate and yield for 
most species in the presence of metabolic byproducts, antibiotics and in a range of different 
environmental pH values (Figure 3.9, 3.10, 3.11, and 3.12). Interestingly, the association 
between growth rate and yield was negatively correlated for S. non-aureus species/strains in the 
presence of both acetic and lactic acid. This effect is due to the increased growth yield in the 
presence of increasing concentrations of either acid, suggesting that S. non-aureus species can 
utilize these metabolic byproducts as an energy source.  
These data demonstrate that the effect of individual growth mediators on growth rate and yield 
are both condition- and species-specific. However, our CFSM results suggest that a complex 
environment consisting of a range of nutrients, byproducts and antimicrobial peptides, affects 
growth dynamics in a linear and predictable manner. Thus, despite our inability to apply general 
principles of growth at the level of individual factors, these principles can be applied to complex 
environments.  
3.2.6 Co-culture Experiments 
To validate our computational model, two-species enrichment experiments were performed. For 
this, fluorescent S. aureus (sGFP) – S. non aureus KPL1850 cocultures with initial populations 
of 1:1, 1:10 and 1:100 (S. aureus: S. non-aureus KPL1850) were grown for 24 hours (37°C with 
shaking). When we compared our modeling results to the coculture experimental results, we 
observed a significant deviation in outcomes. The most distinct difference between the modeling 
and experimental results was the lag time. After incorporating parameters for lag time (2.35 
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hours and 2.25 for S. aureus and S. non-aureus KPL1850, respectively), modeling results had a 
significantly improved fit throughout growth (Figure 3.13, Top).  
The interaction coefficient for each species was calculated over the course of exponential 
growth and compared to the model-based interaction coefficient. To do this, the interaction 
coefficient was calculated after smoothing the experimental data and it was compared with the 
coefficients derived from the CFSM characterizations. The experimental interaction coefficient 
agreed with the model interaction coefficient in sign (i.e., negative interaction) and remained 
generally aligned with the model (Figure 3.13, Bottom).  
 
Figure 3.9. Growth rate-yield results from nasal species grown in the presence of various concentrations of 












Figure 3.10. Growth rate-yield results from nasal species grown in the presence of various concentrations of 
lactic acid (in 10% THY + T80). A linear regression analysis shows weak correlations between growth rate and yield. 
Figure 3.11. Growth rate-yield results from nasal species grown in the presence of various concentrations of 
the antibiotic vancomycin (in 10% THY + T80). A linear regression analysis shows weak correlations between 





Figure 3.12. Growth rate-yield results from nasal species grown in different environmental pH. A linear 
regression analysis shows weak correlations between growth rate and yield. 
 
3.3 Discussion 
The Lotka-Volterra model consists of a set of equations that model trophic relationships 
between an arbitrary number of species, making it a useful theoretical framework for describing 
interactions between species competing for a shared resource. The advantage of this model lies 
in its simplicity. For two interacting species, only six parameters easily derived from 
experimentally measured time-resolved population density data are required: growth rates, 
carrying capacities, and species interaction coefficients.  
 
The original Lotka-Volterra model was first used to describe competitive predator-prey 
interactions but has since been adapted for a broader range of ecological problems. As first 
proposed by Jansen (1987), Lotka-Volterra equations have been used extensively to create 
microbial interaction networks from metagenomic data and predict community outcomes given a 
set of defined interactions (345,362–366). Lake ecosystems (367), the human gut (345,363,368) 
and cheese-associated microbial communities (366,368) are just a few examples for which 






Figure 3.13. Comparison of experimental and modeling results for sGFP S. aureus (Sa) and S. non-aureus str 
1850 (Sna) cocultures. Top: Coculture experiments and simulations were performed as described in the Methods 
section. After incorporating parameters for lag time, modeling results were comparable to the experimental outcomes 
throughout exponential and stationary growth phases. Bottom: Interaction coefficients derived from CFSM 
characterizations (dotted) approximated the values inferred from measured population dynamics (circles). Fitting an 
LV model into measured dynamics using the two interaction coefficients as degrees of freedom (dashed) also offered 
an acceptable approximation.   
 
In our experiments, we observed a positive correlation between growth rate and yield for nasal 
isolates grown in low nutrient conditions, including CFSM. This data is consistent with a LV 
representation of interactions which assumes that the growth rate-yield ratio of a species grown 
in the presence of another species is equivalent to that of the species grown in monoculture.   
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However, when isolates were grown in the presence of individual factors commonly found to 
mediate community structure (metabolic byproducts, antibiotics, varying environmental pH), 
results were highly condition- and species-dependent. For metabolic byproducts, the growth 
rate-yield relationship was only weakly linear for some species, while others displayed a  
negative correlation. Species also had distinct sensitivities to antibiotics and environmental pH. 
These results suggest that general principles of growth captured by LV equations can describe 
community dynamics in complex environments, despite the inconsistent effects of individual 
growth mediators.  
 
To test this hypothesis, we created a simple modeling framework to describe nasal microbiota. 
Similar to previous work, we find that this logistic model allows us to accurately describe growth 
dynamics of nasal isolates in coculture over exponential growth. Thus, simple in vitro 
experiments, such as CFSM experiments, can be used to indicate the effectiveness of a LV-like 
model in describing the microbial community of interest. If growth rate and yield are linearly 
correlated for all species grown in the presence of CFSM, we hypothesize that a LV model is 
appropriate and sufficient for predicting coculture outcomes.  
 
Although our framework is a good first-step towards identifying which model-type is appropriate, 
further research is required to determine when this theory applies and in what scenarios it fails.  
For instance: 1) in what conditions are growth rate-yield linearly correlated (and a LV-like model 
can be used), and 2) at what level of complexity does this framework fail?  
 
3.3.1 Growth Rate and Yield are Positively Correlated in Low Nutrient 
Environments and Negatively Correlated in High Nutrient Environments 
Previous research is inconclusive about the correlation between growth rate and growth yield 
(369). In 1965, Pirt proposed the maintenance energy theory which stated that the amount of 
energy required for cell maintenance remains the same, despite slow growth rate (370). Thus, 
when a species’ growth rate is slow, the observed yield also decreases, resulting in a positive 
linear relationship between growth rate and growth yield. In contrast, a distinct body of work 
supports a negative relationship between growth rate and yield which argues that rate-yield 
tradeoffs are central to the coexistence of species (369,371–374). Considering this explicit 
discrepancy, Lipson attempts to reconcile these distinct theories under a single broad 
perspective (369). In his 2015 paper he rationalizes that positive growth rate-yield correlations 
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are often observed in low nutrient or physiologically stressful environments whereas rate-yield 
tradeoffs occur under nutrient-rich conditions. Indeed, when nasal species were grown in 
dilutions of nutrient-rich media, we observe a negative growth rate-yield relationship at higher 
nutrient concentrations and a positive relationship at lower nutrient concentrations. 
 
Resource competition is one of the major principles governing the organization and function of 
microbial communities in low nutrient and/or physiologically stressful environments (375). Thus, 
a LV-like model – which captures interactions via resource competition – can be applied to a 
broad range of biologically-relevant environments since growth rate and yield are equally 
modulated under these conditions.  
3.3.2 LV Modeling Results for Multi-species Communities are Inconclusive 
Some evidence suggests that LV pairwise models fail in more complex communities 
(347,348,376), largely due to higher order effects. LV models assume that the fitness of an 
individual is equal to its basal fitness plus the fitness influences from pairwise interactions 
(“additivity assumption”). This means that in a more complex community of 3 or more species, 
all fitness influences on an individual are summed up into a single fitness parameter and higher 
order effects are essentially ignored.  
 
Yet, others have shown that pairwise interaction data is sufficient for describing more complex 
microbial communities, despite the presence of higher order effects (338,339,345,346). In one 
such study on gut microbiota, Venturelli and colleagues found that pairwise interaction data was 
able to accurately predict outcomes for 11- to 12-species communities (339), thereby, 
supporting the use of simple bottom-up approaches to predict microbial community structure.  
3.3.3 A Simple Framework is Helpful in Determining the Suitability of a LV-like 
Model, but not Sufficient  
Many experimental and biological conditions include variables which can lead to the failure of 
LV-like models. Identifying all potential variables that contribute to such a failure requires an 
insurmountable amount of work. So, if instead, a method was available to identify a proper 
modeling framework, one could quickly determine whether a LV-like model was suitable for the 
system of interest. In this study, we propose a simple, easily testable, framework to determine 
when a LV-like model is appropriate. However, we recognize that these tests are not enough to 
predict the success of such a model—especially when handling multispecies communities—and 
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that further research is required to determine the scope of application and the limits of such a 
framework.  
 
3.4 Materials and Methods  
3.4.1 Bacterial Strains  
All nasal isolates were provided by Dr. Katherine Lemon (Baylor College of Medicine, Houston, 
TX). Species were isolated from the anterior nares of two patients: one Staphylococcus aureus 
carrier and one non-carrier. Species isolated from the S. aureus carrier include 
Corynebacterium tuberculostearicum strain KPL1821, Staphylococcus non-aureus strain 
KPL1839, and Staphylococcus non-aureus strain KPL1850. Strains derived from the non-carrier 
include Staphylococcus non-aureus strain KPL1867 and Corynebacterium pseudodiphtheriticum 
strain KPL1989. The fluorescent S. aureus – Newman sGFP-S. aureus – used in co-cultures 
was provided by Dr. Nienke de Jong (Novartis Pharma Nederland, The Randstad, Netherlands) 
(377).  
3.4.2 General Experimental Setup 
For all experiments, species were grown in 3 mLs of 100% Todd Hewitt Broth + 0.5% Yeast 
Extract + 1% Tween80 (THY+T80) until mid-exponential growth phase. Cells from each 
monoculture were then centrifuged down and re-suspended in 1x Phosphate Buffered Saline 
(PBS) before transferring a small fraction into the specific testing condition (e.g., media).  
3.4.3 Cell-free Spent-media (Supernatant) Exposure Experiments 
All cell-free spent media (CFSM) exposure experiments were carried out in MOPS-buffered 
THY+T80 diluted to 10% concentration and set to pH 7.2 (10% THY+T80). This media condition 
was selected since it moderately reduces the growth rate and the carrying capacity of each 
species, allowing us to quantify both increases (facilitation) and decreases (inhibition) in growth 
when in the presence of another species’ CFSM (supernatant). Supernatants were prepared by 
inoculating 12 mLs of 10% THY+T80 with cells at an initial OD600 of 0.01 (~8 x 106 CFUs/mL). 
Cultures were grown for ~16-18 hours at 37°C (with shaking), allowing all species to reach 
stationary phase of growth. CFSM was isolated by centrifuging down the cells (4000 rpm for 10 
minutes) and filtering the supernatant through a 0.22 µm syringe filter. The pH of the CFSM was 
then re-adjusted (to pH 7.2). Except for Corynebacterium species, a 0.1 OD600 stock was 
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prepared from monocultures grown to mid-exponential phase, and 50 uLs of this stock was 
added to 1 mL of each of the species’ CFSM (including its own), bringing the final OD600 to 0.005 
for subsequent growth curve experiments. A 0.3 OD600 stock was prepared for C. 
tuberculostearicum (KPL1821) and C. pseudodiphtheriticum (KPL1989), and 150 uLs of this 
stock was added to 1 mL of each species’ CFSM, bringing the OD600 to 0.05 for subsequent 
growth curve experiments. All species-CFSM combinations were transferred to a sterile 384-
well microplate (Greiner Bio-One, U.S.A.)(75 uLs x 4 replicates). The OD600 of each well was 
read every 10 minutes for 24-48 hours using a BioTek Epoch 2 microplate reader 
(www.biotek.com). Growth rate (1/hr.) and carrying capacity (maximum OD600) were calculated 
using code developed in MATLAB® R2018. See Figure 3.1 for experimental setup.  
3.4.4 Growth Experiments  
All species were grown in 100% THY+T80 and prepared as described under General 
experimental setup. To identify growth characteristics of nasal species in different environmental 
conditions we grew each strain in various media types ranging in concentration from 100% to 
0.32%; in the presence of metabolic byproducts and antibiotics; and at various environmental 
pH values. Conditions used are listed in Table 3-1. See Figure 3.1 for experimental setup.   
Table 3-1 Media and environmental conditions used to characterize the growth of nasal species. 
 




N/A 100, 50, 20, 10, 5, 2.5, 1.25, 0.63, or 0.32% 
Brain Heart Infusion 
(BHI+T80) 
pH 7.2 
N/A 100, 50, 20, 10, 5, 2.5, 1.25, or 0.63% 
Baseline Media + Amino 




Metabolic byproduct, Acetic 




Metabolic byproduct, Lactic 
acid ‡ 0%, 0.2%, 0.4%, 0.6%, 0.8%, 1.0% 
10% THY+T80  
(MOPS-Buffered) 
pH 7.2 




Antibiotic, Vancomycin ‡‡‡ 0, 0.025, 0.050, 0.100, 0.125, 0.150, 0.175, 0.200, or 0.250 ug/mL 
THY+T80  
(MOPS-Buffered) Various environmental pH pH 5.1, 5.4, 5.7, 6.0, 6.3, 6.6, 6.9, 7.2, 7.5 
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N/A Not applicable 
† Glacial acetic acid, Fisher Chemical, Fisher Scientific 
‡ L(+)-lactic acid (90% solution in water), ACROS Organics, Fisher Scientific 
‡‡ Gentamicin sulfate salt, Millipore Sigma  
‡‡‡ Vancomycin hydrochloride, Millipore Sigma 
 
 
3.4.5 Two Species Co-cultures (Model Verification) 
To verify that our computational model can predict simple microbial community outcomes, co-
culture enrichment experiments were performed in 10% THY+T80 media. Co-cultures were 
performed for sGFP S. aureus – C. tuberculostearicum KPL1821 and sGFP S. aureus – S. non-
aureus strain KPL1850. All species were grown in 100% THY+T80 and prepared as described 
under General experimental setup. Species were then mixed in a 1:1, 1:10 and 1:100 ratio 
(S.aureus: Species 2) to a 0.01 starting OD600  and distributed into a sterile 96-well microplate 
(x6 replicates each). Plates were read in a BioTek Synergy Mx microplate reader 
(www.biotek.com) set to 37°C with continuous shaking. The OD600 and fluorescence (485 
excitation, 528 emission) of each well was read every 10 minutes for 24 hours. Serial dilutions 
of each replicate were plated on 100% THY+T80 agar plates to verify plate reader results.   
3.4.6 Comparison of Cocultures with a Lotka-Volterra Model Derived from CFSM 
Experiments 
To calculate the OD600 for S. non-aureus KPL1850, GFP signal from sGFP S. aureus was 
converted into OD600 using a calibration curve (GFP vs. OD600 derived from sGFP S. aureus 
monoculture) based on exponential growth (Figure 3.11).  
a = 0.0283 
b = 5.20×10-6 ·(100-F) 
OD = {2.97 × 10−5 ∙ (𝐹 + 200) ; 𝑖𝑓 𝐹 < 3000
−𝑎 + √𝑎2 − 𝑏                    ; 𝑖𝑓 𝐹 ≥ 3000
 
 
The converted OD600 for S. aureus OD600 was then subtracted from the total OD600 to obtain the 
OD600 for the partner strain. All analyses and algorithms were created and run in MATLAB® 
R2018 and are shared on GitHub (https://github.com/bmomeni/nasal-community-modeling). Co-
culture dynamics were simulated based on standard growth parameters for each species 
(growth rate and growth yield of monoculture in 10% THY+T80) and the growth yield of each 
species grown in the presence of other species’ CFSM. When modeling the growth of 
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monocultures, or co-cultures, in the absence of species interactions, we assume that growth 







in which the population density at a given time (𝑑𝑆𝑖/𝑑𝑡) is determined based on the species’ 
baseline growth rate (𝑟𝑖), carrying capacity (𝐾𝑖) along with the current population density (𝑆𝑖). 
Here, the growth rate of a species is modulated by the fraction of the maximum population for 
species i (1 - 𝑆𝑖/𝐾𝑖), so as the population density nears its maximum carrying capacity, the 
growth rate decreases modularly.  
When species interactions are present in a co-culture, we assume that the presence of species j 

















Similar to logistic growth, the growth rate of each species is dependent on its population size 
and carrying capacity. However, in this case, the “effective” growth rate is modulated by the 
presence of other species in the environment. Ki and ri represent the carrying capacity and 
growth rate of species i in a monoculture, respectively. Kij represents the carrying capacity of 
species i in the cell-free spent media of species j, capturing the effect of species j on species i. 
This formulatiosn is consistent with a Lotka-Volterra model in which the coefficients of 
interactions are aij = cij ri / Ki.  
When comparing the coculture experimental data to the modeling results, species-specific lag 
times were included to account for the delayed growth observed empirically. All experimental 
replicates were plotted for each experimental condition along with modeling outcomes (Figure 
5). The interaction coefficient was then calculated for the empirical data over the course of 





Figure 3.14. Fluorescence readings can be converted back to OD in sGFP S. aureus cultures. Growth rate and 
fluorescence are tightly linked in growing cultures of sGFP S. aureus. This relation can be used to derive a calibration 
curve that converts fluorescence readings to corresponding cell density (using OD as a proxy), as described by the 
equation in Methods.  
3.4.7 Model Parameters  
Unless otherwise noted, the following parameters were included in the model:  
Table 3-2 Model parameters used to simulate co-culture results. 
Parameter Description Value 
R1 Growth rate (1/hr.) of species 1 1.85 
R2 Growth rate (1/hr.) of species 2 1.56 
K1 Maximum carrying capacity (OD600) for species 1 0.61 
K2 Maximum carrying capacity (OD600) for species 2 0.35 
K12 Maximum carrying capacity (OD600) for species 1 in the presence 
of the CFSM of species 2 
0.17 
K21 Maximum carrying capacity (OD600) for species 2 in the presence 
of the CFSM of species 1 
0.03 
c12 Interaction coefficient for species 1  
(effect of species 2 on species 1 growth) 
-1.26* 
c21 Interaction coefficient for species 2  
(effect of species 1 on species 2 growth) 
-0.52* 
S10 Initial OD600 of species 1 0.0005-0.005** 
S20 Initial OD600 of species 2 0.005 
T1L Lag time for species 1 (hours) 2.35 
T2L Lag time for species 2 (hours) 2.25 
In this table, species 1 is S. aureus and species 2 is S. non-aureus KPL1850.  
*The interaction coefficient estimated using CFSM characterizations  




3.4.8 Correlated Growth Rate and Yield is Consistent with a Lotka-Volterra-based 
Formulation of Interactions  







Assuming a Lotka-Volterra model, the presence of another species modulates the growth rate 







Calculating the parameters obtained from the cell-free spent media (CFSM), growth of species 1 














Therefore, growth rate in the CFSM assay is 









) = 0 
Therefore, the carrying capacity in the supernatant assay is 
𝐾12 = 𝑆1,𝑐𝑐 = 𝐾1 − 𝑐12𝐾2 
















In other words, the ratio of growth rate to carrying capacity in supernatant assays is 


























2. Chapter 4                                                      
Impact of pH Fluctuations on the Coexistence 
of Nasal Bacteria in an in silico Community  
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Dedrick S, Akbari MJ, Dyckman S, et al. Impact of temporal pH fluctuations on the coexistence 
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4.1 Introduction  
Resident microbes in the human nasal passage protect us from respiratory pathogens 
(378,379). Indeed, previous research shows the role of resident commensals in suppressing 
pathogens, such as Staphylococcus aureus (352,380,381). Investigating how this microbial 
community is formed and maintained can therefore provide powerful insights into microbiota-
based therapies to prevent or treat infections. While such an investigation appears formidable in 
complex environments such as the gut microbiota, it is feasible for nasal microbiota. First, the 
nasal microbiota has relatively low diversity, with the majority of composition often attributed to 
3~8 species (60). Second, the majority of these species are readily culturable aerobically in vitro 
under controlled environments (60,382). Third, both the species and the nasal environment can 
be sampled relatively easily (2,6). The combination of these factors makes the nasal microbiota 
a suitable choice for mechanistic studies of human microbiota and a gateway for more detailed 
studies of human-associated microbiota. Despite these advantages, community-level modeling 
of nasal microbiota has not been discussed adequately so far. A majority of existing work has 
focused on the biology of specific members of the nasal microbiota such as Staphylococcus 
aureus or Streptococcus pneumoniae because of their disease relevance (383–385). Other 
reports have characterized and investigated the interactions among nasal microbes (380,381), 
but often with a focus on the interaction itself , and have only rarely involved the ecological 
consequences for the community (see (2,64,386), for example).  
Many factors, including interspecies interactions (109,378,380), the host immune system (387), 
and resource availability and access (388) can impact the nasal microbiota. However, all these 
factors take place in an environment that may fluctuate over time and vary in space. Previous 
investigations have revealed that the nasal passage is in fact very heterogeneous, both spatially 
and temporally (6). In particular, pH fluctuations (in the range of 5.8-7.2, depending on the 
sampling site and time) were observed within the nasal passage (389,390). Previous studies 
also demonstrated that temporal environmental fluctuations can transition the community to a 
different state (391) or increase and support biodiversity (392–396) . The explanation is often 
based on the temporal niche partitioning mechanism; i.e., environment variations creates 
additional niches and allow for more species to coexist (397,398). The purpose of our work is 
not to introduce a new theoretical framework for modeling microbial communities. Instead, we 
aim for a predictive mathematical model to study the impact of temporal pH fluctuations on the 
nasal microbiota composition. Other factors notwithstanding, we specifically ask whether, and 
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when, incorporating temporal pH fluctuations is necessary to accurately predict compositional 
outcomes.  
To answer the above question, we first characterize six nasal bacterial isolates as 
representative of members present in the nasal community. The rationale behind choosing 
these nasal bacteria was that (1) we can culture these strains reliably in the same cultivation 
medium and conditions in the lab; (2) covering different Corynebacterium and Staphylococcus 
species, these strains capture some of the natural diversity of microbiota (60); and (3) Some 
interactions among these strains has already been identified (109). For instance, C. accolens 
inhibits S. aureus through short-chain fatty acids (378) and S. aureus promotes the growth of C. 
accolens and gets inhibited by C. pseudodiphtheriticum (2). We then use in vitro communities 
constructed from nasal isolates to quantify the community response to temporal pH variations. 
Then, with parameters relevant to nasal microbiota, we use a phenomenological model to 
represent microbes and their interactions in an environment with a temporally fluctuating pH. 
Based on our empirical characterizations of nasal bacteria, we construct in silico examples of 
nasal microbiota and quantify their response to temporal pH fluctuations. Our simulation results 
suggest that temporal pH fluctuations do not have a major impact on the stable coexistence of 
nasal bacteria. The outline of our procedure to assess the impact of temporal pH fluctuations on 
nasal microbiota is shown in Figure 4.1. 
 
Figure 4.1 The outline of the procedure for assessing the impact of temporal pH fluctuations on nasal 
microbiota is shown. To assemble in silico nasal communities, we characterized 6 bacterial nasal isolates. We then 
created in silico strains by randomly modulating the parameters of each characterized strain—schematically 
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illustrated as different shades for each species. Using random assemblies of such strains, we simulated the 
enrichment process to find instances of stable nasal communities. We exposed these communities to a fluctuating pH 
and compared how the community composition was affected. 
 
4.2 Results  
4.2.1 In vitro Characterization of Nasal Bacteria  
We experimentally characterized how six representative nasal bacterial strains respond to 
different pH values in their environment. These bacterial strains were chosen from a set of 
isolates (see Methods) based on three major considerations: (1) they reliably grow in our 
cultivation media under an aerobic environment; (2) they include commonly observed 
Staphylococcus and Corynebacterium species; and (3) they span the phylogenetic landscape of 
both closely and distantly related bacteria found in the nasal environment (60). We assumed 
that each of these characterized strains is a representative strain of the corresponding species.  
We first characterized the pH response of each strain by growing them under different 
environmental pH values. Different strains exhibited different degrees of pH dependency in their 
growth rates and carrying capacities (Figure 4.2, 4.3, and 4.4). Among these strains, S. 
epidermidis, S. non-aureus 1, and S. non-aureus 2 show fairly similar growth properties. We 
chose to treat these as separate species in our investigation, because—as shown later—they 
had considerably different interactions with other species (Figure 4.3). 
 
 
Figure 4.2 Growth properties of nasal bacterial isolates are pH-dependent. Growth is characterized using the 
growth rate in the early exponential phase (A), and the carrying capacity based on optical density (OD, absorption 
measured at 600 nm) as a proxy (B). Each data point is the average of at least 6 replicates from two independent 
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experiments. Error-bars are not shown to avoid overcrowding the plot but the values are available in the raw data. In 
all cases, growth is experimentally tested in a 10-fold diluted Todd-Hewitt broth with yeast extract (10% THY). 
 
We then examined how different species interacted with one another. For this, we grew each 
species to its stationary phase in a monoculture, filtered out the cells, and measured how other 
strains grew in the resulting cell-free filtrates (see Methods; similar to (109,338)). From these 
measurements, we estimated the inter-species interaction coefficients based on the generalized 
Lotka-Volterra (LV) model (Figure 4.5; see Methods). In this formulation, baseline competition 
with complete niche overlap will result in an interaction coefficient of -1. Of note, from our 
experimental data we cannot distinguish the relative contribution of competitive niche overlap 
and interspecies facilitation. Nevertheless, for simplicity we only use “facilitation” for extreme 
cases in which facilitation outweighs competition and the interaction coefficient turns positive. 
We interpret different gradations of negative interaction coefficients from -1 to 0 as different 
degrees of niche overlap (with -1 indicating complete niche overlap), and cases with interaction 
coefficients less than -1 indicate inhibition beyond competition for resources. Among the 30 
pairwise interaction coefficients, there were 3 positive values (bright blue, marked by ‘+’ in 
Figure 4.5). For simplicity, throughout this manuscript, we assume that these interaction 
coefficients are not pH-dependent. 
4.2.2 In silico Assembly of Nasal Bacterial Communities 
To capture some of the diversity of nasal microbiota, we propose that other in silico strains of 
each species can be constructed by randomly modulating the measured properties of that 
species (i.e. growth rate, carrying capacity, and interaction coefficients). We chose the degree 
of strain-level modulation to be up to 20%, as a balance between intraspecies and interspecies 
diversity (Figure 4.6).  
To assess the response of nasal microbiota to temporal fluctuations in the environment, we first 
construct an ensemble of in silico communities that represent a subset of possible nasal 
communities. This is chosen as an alternative to performing an in vivo study, because 
performing these experiments with human subjects is not feasible and there is no reliable 
animal model for human nasal bacteria. Our approach is in essence similar to several other 
previous work that have used simple models to describe the dynamics of human-associated 
microbiota (338,339,345,363,368). Compared to in vitro studies, these in silico communities 




Figure 4.3 Nasal species exhibit different growth properties when grown at different pH values. For two 
representative pH values (5.4 and 7.5) the growth dynamics of the six nasal species studied in this work are shown 
(using OD as a proxy). Results are shown for 3 replicates in each case, after subtracting the background OD. The 







Figure 4.4 Growth properties of nasal bacterial isolates are pH-dependent. Growth is characterized using the 
growth rate in the early exponential phase (A), and the carrying capacity based on optical density (OD, absorption 
measured at 600 nm) as a proxy (B). Each data point is the average of at least 6 replicates from two independent 
experiments. Error-bars show standard deviations among different replicates around the mean value. Growth 
conditions match those listed in the Methods section. 
 
 
Figure 4.5 Interaction coefficients among pairs of nasal bacteria. Values represent interaction coefficients in a 
Lotka-Volterra model. In each case, the growth of a recipient strain is measured when the strain is exposed to cell-
free filtrate derived from the effector strain. Positive mean coefficients (indicating facilitation) and negative mean 
coefficients below -1.2 (indicating strong inhibition) across different replicates are marked by ‘+’ and ‘-,’ respectively. 
Standard deviations (shown for each value) are calculated based on empirical standard deviations of measured 
carrying capacities in monocultures and supernatant experiments. Diagonal elements are set to -1, indicating 






Figure 4.6 The degree of intraspecies parameter variations is chosen as a balance between strain-level and 
species-level diversity. Starting from communities that had a balanced representation of different strains (top), we 
observed that after community assembly (bottom), the prevalence of different species was affected. The prevalence 
here is defined as the average number of in silico strains from each species that appeared in each community. The 
pattern was more pronounced with smaller strain-level variation of 10%, and as this variation increased to 30%, the 
diversity between different species decreased and species prevalence became more uniform. We chose the strain-
level variation of 20% to maintain some strain-level diversity, without diminishing species-level diversity. Number of in 




contributing to sensitivity to pH fluctuations (399). To construct in silico communities, we 
mimicked enrichment experiments (340,400) by simulating the dynamics of an initial 
assemblage of 20 strains (sampled from the space of in silico strains) until the community 
reached stable coexistence. These in silico communities were largely robust against 
experimental noise in characterization (Figure 4.7). The interspecies interactions in our model 
appear to be instrumental in the assembly of these in silico communities, as evidenced by 
changes when we assigned the interaction coefficients at given levels (Figure 4.8A) or 
modulated the measured interactions (Figure 4.8B). To assess how pH fluctuations in the 
environment influence nasal communities, we take several instances of in silico nasal 
communities, expose them to a fluctuating pH, and quantify how the community composition is 
affected. The entire process is outlined in Figure 4.1. 
4.2.3 In silico Nasal Communities are Diverse and Favor Facilitation  
We first examined the properties of assembled in silico communities at various pH values with 
no temporal fluctuations. We found that the prevalence of different species were distinct and 
pH-dependent (Figure 4.9). This prevalence is a result of nasal species’ pH-dependent growth 
properties as well as their interspecies interactions.  
We also found that during the process of assembling in silico communities, the prevalence of 
interspecies facilitation interactions increased. Comparing the prevalence of facilitation in initial 
assemblages of strains versus the final stable communities, we found that among the 
communities that had at least one facilitation interaction at the start of the in silico enrichment 
(89% of communities), facilitation was enriched in ~66% of the final community assemblies 
(Figure 4.10). 
4.2.4 Temporal pH Fluctuations only Minimally Impact Nasal Microbiota 
Composition 
Next, we asked how the temporal variation in the environment might influence the community 
composition. To answer this question, we used instances of in silico communities to evaluate 
the impact of temporal pH fluctuations. We assumed a continuous growth situation in which all 
community members experience a constant dilution rate. This dilution mimics the turnover in 
microbiota, for example, when the mucosal layer gets washed away. To avoid situations in 
which the in silico community itself was not stable, we changed the dilution rate by ±50% and 
only kept the communities for which the modified dilutions only caused a small deviation in 





Figure 4.7 Sensitivity analysis shows that in silico communities are largely insensitive to measurement 
noise. To assess whether in silico communities were sensitive to experimental error in characterizing species 
parameters, we intentionally introduced change in measured parameters and quantified the resulting change in 
community composition. We observe that even when we changed all parameters by up to 10% using a uniform 
distribution, in silico community compositions were hardly affected. Number of cases examined, n = 10,000. 
 
 
Figure 4.8 Assembly of in silico communities is affected by interspecies interactions. To assess the impact of 
interactions, in our model (A) we assigned all off-diagonal interaction coefficients to a fixed number, cij, or (B) 
modulated all experimentally measured off-diagonal interaction coefficients by a fixed factor, m. Both results show 
that when negative off-diagonal terms (i.e. non-self competitions) are weaker, there is more coexistence. In all cases 
and for all species, we assumed cii = -1. Error-bars show bootstrap 95% confidence intervals of the mean values. 




Figure 4.9 Communities assembled at different pH values show distinct and pH-dependent profiles of 
species-level prevalence. We binned simulated communities assembled under a fixed-pH regime according the pH 
and within each bin assessed how often different species appeared in assembled in silico communities. The 




Figure 4.10 Prevalence of interspecies facilitation increases in stable in silico communities. Using the 
empirically measured parameters for species growth and interactions, we assembled communities based on in silico 
strains that resembled those species. We then examined how the fraction of interactions among final assembled in 
silico communities was related to the pool of species before assembly. We found that among cases that contained 
facilitation interactions in the initial pool of species, the final stable communities were more likely (66%:34%) to 
contain a higher fraction of facilitation interactions. Because there is no example of mutual facilitation among our 





Figure 4.11 In silico communities that are sensitive to dilution rate changes show higher deviation when 
exposed to fluctuation pH compared to communities that are robust to dilution rate changes. Depending on 
the sensitivity of community composition to changes in dilution rate, we grouped in silico communities to robust 
(<=10% dissimilarity in composition under ±50% change in dilution rate) versus sensitive (>10% dissimilarity under 
±50% change in dilution rate). When these communities were exposed to a fluctuating pH, we observed that sensitive 
(compared to robust) communities were more prone and showed a larger dissimilarity in composition. Among both 
sensitive and robust communities, dissimilarity in composition increased when the amplitude of pH fluctuations 
increased. Number of cases examined, n = 10,000. 
 
more sensitive to dilution rates are also more sensitive to pH fluctuations (Figure 4.11). In all 
cases, composition deviations were calculated using the Bray-Curtis dissimilarity measure (see 
Methods).  
To evaluate the impact of pH fluctuations, we simulated a controlled sinusoidal pH variation over 
time, with two parameters: the amplitude and frequency of temporal variations. Thus, 𝑝(𝑡) =
𝑝0 + ΔpH sin (2𝜋𝑓𝑝𝐻𝑡). Keeping the frequency of fluctuations fixed (fpH = 0.2/hr), we observed 
that the deviation in population composition increased with an increasing pH fluctuation 
amplitude (ΔpH). However, the resulting dissimilarity in population composition was mostly 
minor, with >85% of cases showing less than 0.2 dissimilarity even when the amplitude of pH 
fluctuation was set to 1 (Figure 4.7A). We then examined the impact of the frequency of pH 
variations, while we kept the amplitude of pH fluctuations fixed (ΔpH = 0.5). At intermediate 
frequencies, the pH fluctuations caused the largest dissimilarity in community composition 
compared to stable communities with fixed pH (Figure 4.7B). 
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We repeated the assessment of pH fluctuations by assuming a pH that randomly fluctuated 
between two discrete pH values to ensure that our results were not limited to sinusoidal 
fluctuations. The results were overall consistent with sinusoidal pH fluctuations (Figure 4.12): 
(1) larger pH fluctuation amplitudes increased the deviation in population composition, but 
overall the majority of communities only experienced modest deviations; and (2) pH fluctuations 
at intermediate frequencies had the largest impact on community composition.  
4.2.5 Interspecies Facilitations Dampen the Impact of Temporal Fluctuations  
To explain the low sensitivity of community composition to pH fluctuations, we hypothesized that 
interspecies facilitation stabilizes the composition by creating interdependencies within the 
community. From the data in Figure 4.13, we picked and compared communities with low 
(“competitive,” 0% facilitation) and high (“cooperative,” 50% facilitation) prevalence of 
facilitation. The 0% facilitation corresponds to situations where none of the strains facilitate any 
of the other members of the in silico community. In contrast, 50% facilitation happens when half 
of the pairwise interactions among the in silico community are facilitative. Since in our dataset  
 
 
Figure 4.12 A randomly fluctuating pH shows trends similar to a sinusoidal pH variation in how composition 
deviations (quantified using Bray-Curtis dissimilarity) depend on the frequency and amplitude of 
fluctuations. Unlike sinusoidal changes in pH in the main body of the paper, here pH transitions randomly between 
two distinct pH values, with time between transitions following an exponential probability distribution (i.e. transition 
times following a Poisson distribution). In these results, the average frequency of pH transitions is fpH = 0.2/hr and the 






Figure 4.13 Nasal microbiota composition is robust against pH fluctuations. (A) For a fixed fluctuation 
frequency (fpH = 0.2/hr), larger fluctuation amplitudes increase how the community composition deviates from the no-
fluctuation steady state (as quantified with composition dissimilarity). (B) The impact of temporal fluctuations is 
maximum at intermediate frequencies. Here, the pH fluctuation amplitude is fixed (ΔpH = 0.5). Number of in silico 
communities examined for each condition: n = 10,000. 
 
(Figure 4.5) there were no instances of mutual facilitation, 50% facilitation is the maximum 
fraction that cooperative communities can reach. The results show that cooperative 
communities have a consistently and significantly lower composition deviation when exposed to 
temporal pH fluctuations (Figure 4.14). 
To further explore the impact of facilitation, we asked how interspecies niche overlap (the 
magnitude of negative interspecies interactions) and prevalence of facilitation (the fraction of 
interspecies interactions that are positive) contribute to sensitivity to pH fluctuations. In our 
results, we found that larger interspecies niche overlap leads to more sensitivity to pH 
fluctuations (Figure 4.15A). This trend holds except when interspecies niche overlap 
approaches 1; at such high overlaps, the community loses diversity (Figure 4.15B), becoming 
less sensitive to pH fluctuations. When we directly changed the prevalence of facilitation, we 
observed that with higher prevalence of facilitation the communities became more diverse and 





Figure 4.14 Cooperative communities are more robust against pH fluctuations compared to competitive 
communities. For competitive (those with 0% facilitation among members) and cooperative (those with 50% 
facilitation interactions among members) communities, dissimilarity medians were 0.057 and 0.055 and dissimilarity 
means were 0.12 and 0.058, respectively (p = 1.2×10-6 with a Mann-Whitney U test). pH fluctuates sinusoidally with a 
frequency of fpH  = 0.2/hr and an amplitude of ΔpH = 0.5. 
4.3 Discussion  
Using empirically measured species properties, we assembled stable in silico communities that 
show coexistence of nasal bacteria. When these communities were exposed to a fluctuating pH 
environment, we observed that the composition of stable communities was only modestly 
affected. Larger pH fluctuations increased the deviation, as expected; however, even at a pH 
fluctuation of 1 which exceeds the observed temporal variation in the nasal passage, the 
composition of the majority of communities remained minimally affected. We also found that 
intermediate frequencies of temporal pH fluctuations caused the largest deviations in community 
compositions. Finally, in our results, communities with more facilitation interactions were more 
robust against pH fluctuations.  
To create a predictive model for nasal microbiota, we have extended the generalized Lotka-
Volterra (gLV) equations to study the impact of pH fluctuations on community composition. 
Generalized Lotka-Volterra equations have been previously used to investigate species 
interactions in the human gut (363,368) and in a cheese-associated microbial community 
(366,368). It has also been similarly extended to describe the impact of environmental 
fluctuations (antibiotics) on gut microbiota (345,368). We find that this simple model allows us to 
integrate and incorporate growth dynamics of individuals species, species-species interactions, 
and temporal environmental fluctuations over time. Other models originally designed for single 
species populations can also be adapted to characterize microbial communities. Community 
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ecology modeling frameworks designed to understand interactions at the macro scale—in both 
space and time—have been applied to microbial populations to study the dynamics of 
succession and restoration, along with the impact of environmental disturbances (401,402). For 
example, flux balance analyses, a mainstay in microbial metabolic models, can be modified to 
describe species interactions within a complex microbial community over time (403–409). In 
choosing an appropriate model, one must carefully consider the processes of interest and the 
required level of abstraction to capture those processes (399,410). 
 
 
Figure 4.15 Lower niche overlap and more prevalent facilitation decrease the sensitivity to pH fluctuations. 
(A) As we artificially increased the strength of niche overlap (by setting all off-diagonal coefficients in the interaction 
matrix to be a fixed negative number and making that number more negative), the sensitivity to pH fluctuations 
increased. This trend is disrupted when niche overlap approaches 1, because a majority of communities under such 
conditions lose interspecies diversity (B). As we increased the prevalence of interspecies facilitation by randomly 
setting a given fraction of interaction coefficients to be positive, the communities became less sensitive to pH 
fluctuations (C) and more diverse in species richness (D). Here pH fluctuations are sinusoidal, with fpH = 0.2/hr and 
ΔpH = 0.5. 
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Here, we chose to use a simple Lotka-Volterra-type model that seems to, at least to the first-
order, capture species growth, interactions, and pH-dependence.  
One important aspect of temporal fluctuations is their time scale. Even though in nature the 
fluctuations are not completely regular, our investigation with sinusoidal temporal fluctuations 
reveal the time scale at which the influence on community composition is the strongest. Our 
analysis reveals that the fluctuations are more impactful at intermediate frequencies between 
two extremes (see Methods). At very low frequencies of pH fluctuations, the community 
dynamics are faster than pH changes; thus we can assume the quasi-static approximation 
applies. In this regime, the community reaches its stable state locally (in time), and the 
composition follows the value of pH at any given time, regardless of the frequency of the pH 
fluctuations. In the other extreme, at very high frequencies of pH fluctuations, the population 
dynamics cannot follow rapid changes in pH and essentially the species “see” the average pH.  
An analysis based on the Wentzel–Kramers–Brillouin (WKB) approximation suggests that in this 
regime, the magnitude of change in composition (compared to the composition at the average 
pH) is inversely proportional to the pH fluctuation frequency. Between these two extremes is the 
zone that exhibits the most change in community composition with pH fluctuations (Figure 
4.12B and 4.13B). However, for parameters relevant to the nasal strains we are analyzing, 
even in this zone the changes in community composition are not drastic. 
Our focus in this manuscript is on how composition of stable communities changes when 
environmental pH fluctuates. Another relevant question is how fluctuations in pH affect the 
process of community assembly. For this, we repeated the community assembly simulations 
(Figures 4.9 and 4.10), but under an environment in which the pH temporally fluctuated. 
Contrary to our expectation, the richness of resulting communities did not monotonically 
increase with an increase in the amplitude of pH fluctuations, regardless of fluctuation frequency 
(Figure 4.16). Instead, we found that richness only changed in a small fraction of in silico nasal 
communities. Furthermore, in cases with increased richness, S. non-aureus 1 (most facilitative 
species in our panel) was most frequently added to the community, whereas in cases with 
decreased richness, S. epidermidis (most inhibitory species in our panel) was most frequently 
dropped from the community (Figure 4.17). This observation underscores the relative 
importance of interaction (compared to niche partitioning) in richness outcomes in our model of 
nasal communities. Our finding is also consistent with predictions about augmentation and 
colonization resistance using a mediator-explicit model of interactions (411). 
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There are some limitations and simplifications in our study. First, in our investigation we have 
assumed that fluctuations in pH are imposed externally (e.g. by the host or the environment). It 
is also possible that species within the nasal community contribute to the environmental pH. 
Although outside the scope of this work, we speculate that if species within the community drive 
the pH to specific values (412,413), the impact of external temporal fluctuations of pH on 
community composition will be even more diminished. Second, in our model, we assumed that 
interactions among species remained unchanged at different environmental pH values. We 
examined in silico how pH-dependent interaction coefficients might affect our results. For this, 
we assumed that interaction coefficients changed linearly with pH in each case (see Methods) 
and asked how strong the dependency had to be to considerably change the community 
composition under a fluctuating pH. We observed a significant impact only when the interaction 
coefficients were strongly pH dependent (i.e. to the level that the sign of interactions would 
change within the range of pH fluctuations) (Figure 4.18).  
Our work suggests that a shift in pH can change the community composition and coexistence 
(Figure 4.9). This is consistent with previous observations from profiling different locations 
along the nasal passage (2). However, our prediction is that temporal pH fluctuations often do 
not cause a major shift in community structure. As a future step, we plan to verify this prediction 
experimentally by testing how pH fluctuations affect in vitro nasal communities. If confirmed, our 
prediction is that the spatial position of sampling and the heterogeneity of the environment will 
have a stronger effect on community composition compared to the temporal resolution of 
sampling. The practical implication is that microbiome profiling of nasal microbes may not 
require a high temporal resolution. We proposed that high throughput sampling of the nasal 
microbiome along with the corresponding pH would be an insightful future step to test our 
predictions. 
Finally, one of the main messages of our work is that nasal microbiota is insensitive to temporal 
fluctuations in pH. It is tantalizing to speculate, when examining other microbial communities, 
under what conditions this statement is valid. Recent work by Shibasaki et al (414) shows that 
under a fluctuating environment species properties play an important role in community 
diversity. Our results corroborate their finding. Insensitivity of the members to the environmental 
fluctuations—as trivial as it may sound—is a defining factor for how sensitive the community is. 
In the nasal microbiota, species that we are examining are adapted to the nasal environment 
and the range of pH fluctuations experienced in this environment is not large. As a result, the 
community is not majorly affected by pH fluctuations. On top of this, we also observe that 
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interactions—in particular, facilitation and competition—can act as stabilizing or de-stabilizing 
factors for how the community responds to external variations. In other words, facilitation 
between community members acts as a composition stabilizing factor between populations, 
which lowers the impact of external fluctuations (Figure 4.15A). In contrast, inhibition between 
community members typically exaggerates the changes introduced by external fluctuations 
(Figure 4.15C). 
 
Figure 4.16 If pH fluctuates during community assembly, the richness of resulting communities could be 
different from the fixed-pH case. However, unlike theoretical predictions, the richness does not monotonically 
increase when the amplitude of pH fluctuations increases. We examined fluctuations at different frequencies and 
observed little dependence of the outcome on the pH fluctuation frequencies. Nasal microbiota assembly is only 





Figure 4.17 Species with the most facilitation are most likely to be added into and species with the most 
inhibition are least likely to drop from nasal microbiota that are assembled under a fluctuating pH. We 
enumerated the probability at the species level that a member would be (A) added to or (B) dropped from a 
community during assembly when the pH fluctuated (compared to the fixed-pH case). The amplitude of pH 
fluctuations tested varied from 0.1 to 1 and the frequency of fluctuations tested varied from 0.02/hr to 1.28/hr (similar 
to Fig S10). Number of assembly cases at each fluctuation frequency, n = 1,000. 
 
 
Figure 4.18 With temporal fluctuations in pH, pH-dependency of interaction coefficients affect the community 
composition only when the dependency is very strong. We allowed interaction coefficients to each linearly 
change with pH with a slope randomly selected from a uniform distribution in the range [-m, m]. (A-C) Under a 
temporally fluctuating pH, as the strength of pH dependency of interactions (i.e. m) is increased, we observe more 
deviation from the stable community composition. For each m in (A-C), the composition deviates more as the 
amplitude of pH fluctuation increases, consistent with our results for pH-independent interactions in Fig 4. (D) 
Comparing the results for simulated cases with a pH fluctuation amplitude (ΔpH) between 0.4 and 0.6, we note that 
the effect of pH-dependent interactions on composition deviation is minimal until the dependency becomes strong 
enough that the change becomes comparable to the interaction coefficients themselves (m > 0.4). The frequency of 
fluctuations fpH = 0.2/hr (similar to Fig 4). Number of communities examined, n = 10,000. 
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4.4 Materials and Methods  
4.4.1 Nasal Bacterial Strains  
Six strains used in this study were isolated from two healthy individuals and kindly shared with 
us by Dr. Katherine Lemon (Table 1). Interactions between some of these strains and other 
nasal bacteria has been studied recently (109).  
Table 4-1 Nasal strains used in this study are listed along with their designation based on 16S rRNA gene 
similarity.  
Strain name Genus Most likely species designation 
KPL1821 Corynebacterium Corynebacterium tuberculostearicum  
KPL1828 Staphylococcus Staphylococcus aureus 
KPL1839 Staphylococcus Staphylococcus epidermidis 
KPL1850 Staphylococcus Staphylococcus non-aureus 1 
KPL1989 Corynebacterium Corynebacterium pseudodiphtheriticum 
KPL1867 Staphylococcus Staphylococcus non-aureus 2 
 
4.4.2 Cultivation Conditions and Medium in vitro 
As growth medium, we have used a 10-fold dilution of the Todd-Hewitt broth with yeast extract 
(THY, at an initial pH of 7.2). We have diluted THY to create an environment closer to the 
nutrient richness of the nasal passage (38). For collecting cell-free filtrates, cells were grown in 
15 ml of media in sterile 50-ml Falcon® tubes with loose caps exposed to the room atmosphere. 
For growth rate and carrying capacity characterizations, cells were grown in flat-bottom 96-well 
plates. All cultures were grown at 37°C with continuous shaking at 250 rpm. 
4.4.3 Characterizing the pH Response of Nasal Isolates in vitro 
To assess the response of nasal strains, we grew them in 10% THY after adjusting the pH 
within the biologically relevant range of 5.1 and 7.5 at 0.3 intervals (pH buffered with 10 g/l of 
MOPS). For each strain, we measured the growth rate at low population sizes (before nutrients 
become limiting or byproducts become inhibitory) and the final carrying capacity. These values 
were measured by growing replicates of each strain (typically 6 replicates) in 96-well microtiter 
plates incubated inside a Synergy Mx plate reader. Growth rate and carrying capacity were 
estimated by measuring the absorption in each well (OD600) at 10-minute intervals over 24 hours 




4.4.4 Mathematical Model 
To model the growth of species, we assume that in the absence of interactions, the population 
growth follows the logistic equations: 
𝑑𝑆𝑖
𝑑𝑡
= 𝑟𝑖(𝑝) [1 −
𝑆𝑖
𝐾𝑖(𝑝)
] 𝑆𝑖 − 𝛿𝑆𝑖 
In which 𝑟𝑖(𝑝) and 𝐾𝑖(𝑝) are the pH-dependent growth rate and carrying capacity of species i. In 
our simulations, the growth rate and carrying capacity values at any given pH are found using a 
linear interpolation from experimentally measured values (pH 5.1 to 7.5 at 0.3 intervals). pH 
dependence is experimentally characterized for each strain in a monoculture, as described 
above, and 𝛿 is the dilution rate. 
When multiple species are present, we assume that the presence of other species takes away 
resources from the environment; as a result, the growth of each species will be modulated as 
𝑑𝑆𝑖
𝑑𝑡
= 𝑟𝑖(𝑝) [1 −
𝑆𝑖 − 𝛾𝑖
𝐾𝑖(𝑝)
] 𝑆𝑖 − 𝛿𝑆𝑖 
where 𝛾𝑖 = ∑ 𝑐𝑖𝑗𝑆𝑗𝑗≠𝑖  and 𝑟𝑖(𝑝)𝑐𝑖𝑗/𝐾𝑖(𝑝) represents the interaction strength exerted on species i 
by species j. Positive values of 𝑐𝑖𝑗 indicate growth stimulation (e.g. via facilitation by producing 
resources) whereas negative values of 𝑐𝑖𝑗 indicate growth inhibition (e.g. via competition). 
4.4.5 Model Parameters 
Unless otherwise specified, the following parameters are used in the model: 
Table 4-2 Modeling Parameters.  
Parameter Description Value 
Nc Maximum number of strains for in silico community assembly 20 
Ns Number of instances of assembly simulations run for each case  10,000 
Ngen Number of generations simulated to obtain stable resident 
communities; also the number of generations simulated to assess 
response to environmental fluctuations 
100 
pHrng Range of pH values (both in experiments and in simulations)  5.1-7.5 
 Dilution rate 0.03-0.3 hr-1 
Next Extinction population density per species (OD) 10-6 
fp Inter-strain parameter variation within each species 20% 
S0 Average initial cell density per strain (OD) 10-4 
fpH Frequency of sinusoidal temporal pH fluctuations 1 hr-1 




Some of these parameters, such as the range, frequency, and amplitude of pH values are 
chosen to keep the simulations close to what is expected in the nasal environment (389,390). 
Some of the other parameters, such as the dilution rate or the initial and extinction population 
densities are not expected to be critical for the overall conclusions of this work. We have chosen 
these parameters to reflect realistic parameters that can be later tested experimentally. Finally, 
parameters such as the number of instances simulated (Ns) and the number of generations 
simulated (Ngen) are chosen to give us enough confidence for our claims, while keeping the 
practical considerations of simulation time and effort in mind. 
4.4.6 Characterizing the Interspecies Interactions Using a Supernatant Assay 
To characterize how species j affects the growth of other species i, we use a supernatant assay 
in which species j is grown to saturation, then all the cells are filtered out using a 0.22 µm filter 
(PVDF syringe filters from Thomas Scientific). The growth rate and carrying capacity of species i 
is then measured when growing in the supernatant taken from cultures of species j. This 
formulation allows us to use the experimentally measurable supernatant responses to formulate 
a dynamical model for mixed cultures of multiple species. 
Assuming a Lotka-Volterra model, the presence of another species modulates the growth rate 
proportionally to the size of the interacting partner, i.e. 
𝑑𝑆𝑖
𝑑𝑡




Calculating the parameters obtained from the cell-free spent media (CFSM), the carrying 




) = 0 
Therefore, the carrying capacity in the supernatant assay (𝐾𝑖𝑗) is 
𝐾𝑖𝑗 = 𝑆𝑖,𝑐𝑐 = 𝐾𝑖 + 𝑐𝑖𝑗𝐾𝑗 





In the particular that species i and j are similar (self-effect), we have 𝐾𝑖𝑖 = 0 and 𝑐𝑖𝑖 = −1. 
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It should be noted that there are limitations in using a Lotka-Volterra model. Such models may 
not accurately represent microbial interactions (347). Additionally, under certain conditions, the 
solutions will exhibit instability. Particularly for this latter case, we examine the situations under 
which “runaway” growth instability may happen. Consider two mutualistic populations: 
𝑑𝑆1
𝑑𝑡
= 𝑟1 [1 −
𝑆1−𝑐12𝑆2
𝐾1
] 𝑆1  
𝑑𝑆2
𝑑𝑡
= 𝑟2 [1 −
𝑆2−𝑐21𝑆1
𝐾2
] 𝑆2  
Instability can happen when the carrying capacity terms fail to act as a negative feedback to 




] > 1 and [1 − 𝑆2−𝑐21𝑆1
𝐾2
] > 1  
This happens when 𝑆1 < 𝑐12𝑆2 and 𝑆2 < 𝑐21𝑆1. Satisfying both of these inequalities requires that 
𝑐12 and 𝑐12𝑐21 > 1, which means strong mutual facilitation. In our dataset, we do not have 
examples of mutual or cyclic facilitation and facilitation interaction terms are small, suggesting 
that instability is not expected in our simulations. Nevertheless, these conditions should be kept 
in mind for other datasets, especially those with strong facilitation between community 
members. 
4.4.7 Calculating Community Composition Deviations 
To compare community composition of a community that experienced pH fluctuation with that of 
the same community simulated at a fixed pH, we calculated the Bray-Curtis dissimilarity 
measure using the f_dis function (option ‘BC’) in MATLAB®. The necessary files to reproduce 
the analysis are included in the accompanied source codes 
(https://github.com/bmomeni/temporal-fluctuations).  
4.4.8 Estimating the Impact of pH Fluctuations 
We consider two extremes, when the fluctuations in pH are (1) much faster or (2) much slower 
than the population dynamics of community members. In both cases, for our formulation we 
define 𝑐𝑖𝑖 = −1 and use the simplified model of populations at different pH:  
𝑑𝑆𝑖
𝑑𝑡
= 𝑟𝑖(𝑝) [1 +
𝛾?̂?
𝐾𝑖(𝑝)




𝛾?̂? = ∑ 𝑐𝑖𝑗𝑆𝑗 
Case 1. Fast pH fluctuations: To estimate how the community responds under a rapidly 
changing pH, we use the framework of the Wentzel–Kramers–Brillouin (WKB) approximation. 
For the general case of 𝑑𝑆
𝑑𝑡
= 𝑟(𝑡)𝑆, we split the population dynamics into two terms, the primary 
exponential term and an envelope function, E, for which 𝐸(𝑡) = 𝑒−𝑟0𝑡𝑆(𝑡) and thus, 
𝑑𝐸
𝑑𝑡
= [𝑟(𝑡) − 𝑟0]𝐸 
Using the WKB approximation E can be written using the expansion  


































= 𝑟(𝑡) − 𝑟0 
Assuming sinusoidal changes in pH, 𝑝(𝑡) = 𝑝0 + 𝑝𝑑sin (2𝜋𝑓𝑡), to the first order, the temporal 








≈ 𝑟𝑑 sin(2𝜋𝑓𝑡) 
In the limit that → 0, the first terms of expansion for E are obtained as 
𝑑
𝑑𝑡
𝐸0(𝑡) = 0, 
𝑑
𝑑𝑡
𝐸1(𝑡) ≈ 𝑟𝑑 sin(2𝜋𝑓𝑡) 
Since the continuous dilutions in our setup keeps the populations finite, 𝐸0 does not affect the 







As a result, 




Importantly, the magnitude of change in this equation drops inversely proportional to the 
frequency of pH fluctuations f. This means that the impact of pH fluctuations diminishes at high 
frequencies, consistent with our intuition that in this case the community dynamics is incapable 
of following the environmental fluctuations and only responds to the mean value. 
Case 2. Slow pH fluctuations: In this case, we assume the quasi-static approximation, in which 
fluctuations are so slow that the community approaches its steady-state at each temporal value 
of pH. In this situation, assuming 𝑑𝑆𝑖
𝑑𝑡
= 0, we can rearrange the equation at steady-state as 
[𝑟𝑖(𝑝) − 𝛿]𝑆𝑖 = −
𝑟𝑖(𝑝)
𝐾𝑖(𝑝)
𝑆𝑖 ∑ 𝑐𝑖𝑗𝑆𝑗 




= ∑ 𝑐𝑖𝑗𝑆𝑗 
This can be written in matrix form as  
[C]𝑆 = 𝑏, 
where [C] contains the interaction coefficients and 𝑏𝑖 = [𝛿 − 𝑟𝑖(𝑝)]
𝐾𝑖(𝑝)
𝑟𝑖(𝑝)
; underline in our notation 
designates a vector. Since the interaction matrix [C] is pH-independent in our model, the 
change in composition within this quasi-static approximation can be expressed as 
[C] (𝑆(𝑡) −  𝑆0) = 𝑏(𝑡) − 𝑏0, 
or 
∆𝑆(𝑡) = (𝑆(𝑡) −  𝑆0) = [𝑪]
−1 (𝑏(𝑡) − 𝑏0) = [𝑪]
−1∆𝑏(𝑡) 
We make an additional simplifying assumption that 𝐾𝑖 and 𝑟𝑖 change similarly with pH. This 
leads to ∆𝑏𝑖 ≈ (𝑟𝑖0 − 𝑟𝑖(𝑡))
𝐾𝑖0
𝑟𝑖0
. This means that the magnitude of change in community 
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composition is the same as the change in the growth rate of species, regardless of the 
frequency of fluctuations, under this regime.  
4.4.9 Allowing pH-dependent interaction coefficients 
To examine how pH-dependent interaction coefficients may affect our results, we assumed that 
each interaction coefficient has a linear dependence on pH with a slope (per unit pH) randomly 
selected from a uniform distribution in the range of [-m, m]. In other words,  
𝑐𝑖𝑗(𝑝) = 𝑐𝑖𝑗(𝑝0) + 𝑚(𝑝 − 𝑝0), 
where 𝑝0=7.2 is the pH at which our characterization is performed. We examined how the 






































3. Chapter 5                                                   
Discussion 
 
This thesis offers unique insights into the role microbiota play in the etiology of upper respiratory 
disease and treatment response while also identifying factors important in driving microbial 
community composition. By using human longitudinal data, in vitro experimentation, and in silico 
modeling, this work offers a comprehensive framework for understanding how we can alter 
microbial communities for therapeutic purposes.  
 
In what follows I will summarize the primary takeaways from my work. First, I address how to 
identify what aspect of host-associated microbiota are influential for treatment. For this, I 
analyze longitudinal gut microbiota data to identify what microbes or metabolites are associated 
with the efficacy of medication in children with asthma. Next, assuming the necessary changes 
for microbiota-based therapy are identified, I ask whether we can formulate predictive models to 
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facilitate the restructuring of a microbiota for desired therapeutic outcomes. Using in vitro 
communities of nasal bacteria as a tractable system, I determine when simple Lotka-Volterra 
model is a suitable representation for microbial interactions. Lastly, I examine in silico the effect 
of pH on microbiota composition to answer when environmental fluctuations—of the type we 
expect human-associated microbiota to experience—will have a major influence.  
 
5.1 Gut Microbiota and Metabolome are Associated with Wheeze and 
Treatment Resistance in Childhood Asthma  
Previous research has substantiated the association between airway and gut microbiota and 
asthma in adults. Yet, research in children has been largely limited to early life (0-1 years of 
age) with very little focus on how gut microbiota contribute to morbidity in children with pre-
existing asthma. Here, I offer a unique look into gut microbiota composition and its association 
with wheeze frequency in children with asthma at age 3 years. In this study, I identified gut 
microbiota and metabolic pathways enriched in asthmatic children with more severe and 
treatment resistant endotypes. 
 
Asthma is no longer considered a single condition, but instead, an umbrella under which many 
disease endotypes reside. Due to its complex nature, no singularly successful therapeutic 
approach has been identified. Currently, inhaled corticosteroids (ICS) are the common 
treatment for uncontrolled asthma in both children and adults (415). Despite their success in 
alleviating mild-to-moderate asthma phenotypes, many asthmatics with a categorically severe 
endotype do not obtain sufficient control over their symptoms. In fact, 45% of adult patients 
respond sub-optimally to inhaled corticosteroids and around 25% do not respond to oral 
corticosteroids, the rescue treatment for unresponsive asthma (292,293). Asthma remains the 
leading chronic disease of children. Around 50% of children with asthma report having one or 
more asthma attacks in the past year and asthma exacerbations remain the third-ranking cause 
of hospitalization among children under 15 years of age (416). This suggests that a large 
proportion of child asthmatics remain unresponsive to treatment.  
 
Increasing amounts of evidence suggest that microbiota contribute to the observed variation in 
ICS response. Most studies remain focused on airway microbiota while very little is known about 
the specific interplay between gut microbiota and its role in treatment response. One goal of this 
study was to investigate the association between gut microbiota and treatment response in 
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children with pre-existing asthma. In this inquiry, I find that children that respond poorly to ICS 
(i.e., high wheeze proportion despite continuous ICS treatment) are enriched in Haemophilus 
parainfluezae and sphingolipid metabolites. Previous work has shown that airway-residing 
Haemophilus species are associated with asthma while Goleva and colleagues provided 
specific evidence for a direct interplay between ICS and H. parainfluenzae (239). A large body 
of evidence also supports a role for sphingolipid metabolites in airway hyperresponsiveness 
which has been shown to vary depending on the asthma endotype (265–268). Interestingly, the 
sphingolipid metabolites enriched in the ICS non-responder subgroup align with metabolites 
previously identified in association with a neutrophilic immune response; an endotype correlated 
with more severe and treatment resistant asthma (251). Taken together, these data further 
strengthen the role of gut microbiota and microbiota-derived metabolites in asthma and 
contributes novel insights into the gut microbiota-treatment response paradigm.  
 
The primary target of most currently approved medications are markers of Th2 inflammation 
such as IL-4, IL-5, and IL-13 (417), leaving patients with non-Th2 and more severe endotypes 
with few viable treatment options. Thus, a more personalized approach based on disease 
phenotype is needed. Initial disease characterization methods often rely on patient-reported 
symptoms, inflammatory markers, and/or a patient’s response to corticosteroids; this, however, 
limits clinicians to only differentiating between allergic and non-allergic endotypes (417,418). 
Yet, a 2013 cluster analysis identified at least 5 phenotypic groups that separated based on age 
of onset, atopy, pulmonary function, and medication requirements along with several other 
factors (418). To move pulmonary therapy into the realm of personalized medicine, future efforts 
require in-depth inquiries into asthma endotypes, including treatment resistant subgroups, to 
determine how they align with specific genetic and microbiota profiles.  
 
Gut microbiota are well-established as major modulators of the immune system, and yet, very 
few medical treatments consider this highly impactful consortia in disease management plans. 
Since the rapid advancement of sequencing and biomolecular technologies, an insurmountable 
amount of gut microbiota compositional data has been produced; and while this provides a 
strong foundation for understanding how microbiota correlate with human health and disease, 
our lack of inquiry into the mechanisms at play limits our ability to apply such knowledge.  
 
Factors thought to influence asthma symptoms and severity are also known to alter gut 
microbiota including diet, probiotic use, and medication. Very few studies have investigated the 
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role of diet, however, one study in school-aged children found that children given a fruit-
vegetable concentrate along with probiotics have improved lung function and were able to 
reduce their use of short-acting medications (419). Some evidence also indicates that the 
administration of probiotics can reduce the number of asthma-related episodes and symptoms 
while simultaneously improving pulmonary function in children with asthma (229,420,421). 
Meanwhile, many reports show a lack of significant improvement in asthma exacerbations, 
wheezing episodes or overall quality of life (422). In fact, animal studies have demonstrated that 
the efficacy of probiotics are highly time-, dose-, and strain-dependent (417). Little evidence 
exists on the effect of asthma medications on microbiota; however, a few studies have brought 
interesting data forward on macrolides. Macrolides, a class of antibiotic, can inhibit the 
activation of pro-inflammatory pathways, regulate neutrophil and macrophage functions, and are 
even able to reverse corticosteroid resistance (423,424). Thus, patients with neutrophilic and/or 
treatment resistant forms of asthma may benefit from macrolide treatment. Interestingly, studies 
conducted by Huang et al (2011) and Slater et al (2014) found that patients with asthma treated 
with macrolides and had improved pulmonary function also had increased airway microbiota 
diversity and a decreased abundance of several pathogenic genera: Pseudomonas, 
Haemophilus, and Staphylococcus (288,425).   
 
Looking ahead: To my knowledge, this study is the first to identify gut microbiota and 
metabolites that are associated with severe and treatment resistant asthma endotypes in 
children with pre-existing asthma. To gain further insight into how microbiota impact asthma 
outcomes, future efforts should focus on: 1) creating microbiota profiles for each asthma 
endotype 2) the interplay between lifestyle factors (diet, probiotic use, medication), gut 
microbiota and asthma, and 3) how gut microbiota composition is impacted/impacts asthma (vs. 
healthy controls), severe asthma endotypes (vs. mild-to-moderate asthma), and treatment 
response (resistant vs. non-resistant). While this work provides support for some of these goals, 
it was an auxiliary study derived from preexisting data. Thus, additional longitudinal studies with 









5.2 When Does a Lotka-Volterra-like Model Represent Microbial 
Interactions? Insights from in vitro Nasal Bacterial Communities   
The primary goal of microbiota-based therapies (MBT) is to alter/manipulate microbial 
communities for a health benefit. One of the first and most successful applications of such 
therapies has been in treating Clostridium difficile infections via fecal microbiota transplantation 
(426). Recent research efforts have also investigated the feasibility of MBTs for treating other 
acute/systemic infections. For example, in the wake of increasing resistance of pathobionts to 
antibiotics, researchers and clinicians alike have turned towards microbiota-based therapies as 
a viable option for treating and/or preventing methicillin-resistant S. aureus (MRSA) 
colonization. An early study used a low virulence strain of S. aureus to prevent nasal 
colonization by more virulent S. aureus strains (427). However, this study was aborted after 
several reports of severe S. aureus infections (428). Since then, other attempts have been 
made to alter the composition of nasal microbiota. In one study by Shinefield and colleagues, 
subjects were colonized with yet another non-virulent strain of S. aureus. This time, they were 
able to show that non-virulent strains of S. aureus can protect the host against MRSA 
colonization by way of nasal inoculation (429). Another report by Uehara and colleagues (2000) 
found that a Corynebacterium species could successfully eradicate S. aureus colonization in 
71% of carriers while other species (i.e., S. epidermidis) failed (352). Since then, few attempts 
have been made to alter nasal microbiota composition via MBT; instead, more recent studies 
have focused on identifying S. aureus drug targets and novel antimicrobials capable of inhibiting 
S. aureus colonization (430). To bring microbiota-based therapies into the purview of future 
investigations, research must harness the tools and technologies offered by modern 
advancements. Past work by Boris (1964) and Houck (1972) demonstrate the complex nature of 
microbial interactions and what these studies lacked is the insight into how introducing novel 
species affects community dynamics (427,428). For this, computational modeling provides a 
powerful tool.  
 
To effectively design intervention strategies to manipulate and restructure microbiota, predictive 
models of community dynamics can be extremely insightful. Because of their relative simplicity, 
Lotka-Volterra models have been adapted to describe microbial community dynamics (345,362–
366). Yet, when this model is appropriate has not been determined. In fact, few studies have 
attempted to create a framework that allows investigators to determine what type of model is 
suitable for their microbial system of interest. I used in vitro experiments of nasal communities 
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under a controlled lab environment to determine when one such model will work for describing 
the community of interest.  
 
I find that LV-like models are suitable for communities and conditions in which growth rate and 
growth yield are similarly modulated. In agreement with Lipson (369), this applied to low nutrient 
environments in which no nutrients were present at saturation. I also find that this holds true for 
species tested in the presence of CFSM. These data follow the standard Monod equations 
which show that growth rate and growth yield decrease/increase equally in the presence of a 
single carbon source at low concentrations (431). Interestingly, this concept did not apply to 
experiments designed to test individual variables. Taken together, this shows that LV-like 
models are suitable for complex, low nutrient environments. Conceptually, this is equivalent to 
considering all factors/interactions as one single “limiting resource”. My data also suggest that 
CFSM experiments can be used to determine whether a LV-like model is suitable for describing 
the community at hand.  
 
Looking ahead: The eloquence of a LV-like model lies in its simplicity; the reason much 
research has turned to this model for describing microbial communities. Its simplicity along with 
its broad applicability makes it a good candidate for testing MBT theories. This work creates a 
platform for establishing the suitability of a LV-like model, however, additional research is 
needed to determine which microbial community characteristics lead to the success or failure of 
such a model. To further develop this framework, future efforts should focus on: 1) identifying 
additional in vitro tests able to decipher the suitability of a LV-like model, 2) characterizing the 
microbial attributes and/or interaction mechanisms that contribute to the success of a LV model, 
3) identifying environmental factors that lead to the success/failure of a LV-like model, 4) further 
verifying the impact of higher order effects, and 5) testing under what conditions pairwise LV-like 
models can be combined to represent multispecies communities. To do this, studies need to be 
carried out in both well-characterized (i.e., communities in which interactions are known) and 









5.3 Nasal Microbiota are Robust Against Temporal Fluctuations in 
Environmental pH  
Microbial communities are impacted by both species’ interactions and environmental factors. 
Previous work has demonstrated that the pH in the nasal passage experiences temporal 
fluctuations, yet how this impacts nasal microbiota is not yet known (389,390). Taking 
advantage of the LV-like model framework developed by our lab, I wanted to explore the impact 
of temporal pH fluctuations on nasal microbiota community assembly and composition. To do 
this, I applied experimental data to a simulated nasal community. In this work, I found  
that the composition of nasal microbiota is robust against pH fluctuations and that community 
richness did not increase with greater pH fluctuation. Nevertheless, communities with increased 
richness often included facilitative species while communities with decreased richness were 
more likely to contain inhibitory species. Moreover, I find that higher proportions of facilitations 
are selected for in in silico enrichment experiments and communities with more facilitative 
interactions were more robust against pH fluctuations (432), corroborating previous conclusions 
published by our lab (400).  
 
Research on microbial communities has focused heavily on species interactions (341,433). Yet, 
a substantial amount of evidence has demonstrated that environmental factors – including pH, 
temperature, spatial parameters, etc. – have significant impact on microbial community 
composition. Similar to work by Shibasaki et al (414), here I have shown that species’ facilitative 
properties were the primary driver of nasal community richness and stability in the face of a 
fluctuating environment. I also show that as the prevalence of facilitation decreases so too does 
the community’s stability.  
 
In the computational model, I made several assumptions: 1) that nasal species do not alter the 
pH of the environment, and 2) species interaction coefficients are not pH dependent.  Yet 
previous work by Ratzke and colleagues has shown that, indeed, species alter the pH of their 
environment and that microbial interactions are mediated through such modifications. They 
found that understanding the extent of each species’ modification of environmental pH and, 
inversely, how environmental pH impacted each species’ fate enabled them to estimate pairwise 
interaction outcomes (412). Based on the current modeling results, I expect that species-
mediated pH changes would drive the pH of the environment to specific values thereby 
minimizing the impact of pH fluctuations even further. However, to potentially improve the 
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accuracy of the model, further research is required to determine if, and how much, nasal 
species alter the pH of their environment and how this impacts the fate of the community.   
 
Additional research is also required to determine the impact of other environmental factors, 
including temperature. Earlier studies – including Monod’s classic work – observed changes in 
bacterial growth strategies in the face of increasing temperatures (369,374,431). Work on 
microbial communities has also shown that environmental temperature can influence microbial  
community composition (434–436).  In the nasal cavity, microbiota experience seasonal 
compositional changes, primarily due to changes in temperature, making a temperature an 
important parameter to consider.  
 
Aberrant nasal microbiota – often associated with a decrease in diversity and an increased 
abundance of gram-negative bacteria – are often observed in acute and chronic infections of the 
nasal cavity (24,437). Environmental factors are an important consideration when restructuring 
nasal microbiota composition as they can dictate the success of therapeutics. If nasal 
microbiota are robust in the face of a fluctuating environment, certain therapies may fail to alter 
the community to a favorable composition. In fact, nasal microbiota are found to be resilient 
against a number of current nasal treatments including topical saline and intranasal steroids 
(24,96). In a cross-sectional study on patients with chronic rhinosinusitis, saline irrigations with 
or without budesonide did not significantly influence sinus nasal community composition (65), 
suggesting that nasal species are robust against alterations in environmental salt 
concentrations. Furthermore, physical features of the nasal cavity, such as muciliary clearance 
and cilia, have been shown to limit dosing of nasally administered drugs (438–440). Thus, 
environmental conditions not only impact nasal microbiota, but also the success-rate of 
treatments aimed at microbiota restructuring.  
 
Microbiota-based therapies are a potential solution to these treatment challenges as nasal 
microbiota are likely to show greater resistance against common mechanisms of muciliary and 
cilia-related clearance. Thus, future efforts in therapeutic development should focus on the 




5.4 Concluding Remarks  
Increased attention has been placed on microbiota-based therapies as a viable treatment option 
for conditions beyond gastrointestinal infections. However, significant gains in knowledge must 
be made to successfully expand their application. Beyond the further characterization of human 
microbiota, efforts are needed to develop predictive tools (i.e., computational models) and to 
identify the factors that should be considered in such tools. This thesis not only provides further 
insight into the association of microbiota with both acute and chronic diseases of the upper 
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